
<html lang="en"     class="pb-page"  data-request-id="799ea609-ce0e-4acc-872a-6165fcbc58af"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-10;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b00441"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Yu  Xue" /></meta><meta name="dc.Creator" content="Peiran  Song" /></meta><meta name="dc.Creator" content="Zilan  Song" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Linjiang  Tong" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Creator" content="Liping  Sun" /></meta><meta name="dc.Creator" content="Hua  Xie" /></meta><meta name="dc.Creator" content="Ao  Zhang" /></meta><meta name="dc.Description" content="An alternative medicinal chemistry approach was conducted on Bruton’s tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two..." /></meta><meta name="Description" content="An alternative medicinal chemistry approach was conducted on Bruton’s tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 1, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00441" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00441" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00441" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00441" /></link>
        
    
    

<title>Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00441" /></meta><meta property="og:title" content="Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0018.jpeg" /></meta><meta property="og:description" content="An alternative medicinal chemistry approach was conducted on Bruton’s tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. 7S was identified as the most potent showing an IC50 value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to 1, 7S was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, 7S showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than 1 (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest 7S as a new BTK inhibitor worthy of further profiling." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00441"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00441">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00441&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00441&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00441&amp;href=/doi/10.1021/acs.jmedchem.8b00441" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4608-4627</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00389" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00115" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-<i>b</i>]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yu Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, and the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Xue">Yu Xue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peiran Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peiran Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peiran++Song">Peiran Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zilan Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zilan Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, and the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zilan++Song">Zilan Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aoli Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aoli Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linjiang Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linjiang Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linjiang++Tong">Linjiang Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meiyu Geng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meiyu Geng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">College of Pharmacy, University of Chinese Academy of Sciences, Shanghai, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">College of Pharmacy, University of Chinese Academy of Sciences, Shanghai, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingsong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingsong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liping Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liping Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>For L.S.: phone: +86-25-83271414; fax: 86-25-83271414; e-mail: <a href="/cdn-cgi/l/email-protection#97f4ffe4fbe7d7f4e7e2b9f2f3e2b9f4f9"><span class="__cf_email__" data-cfemail="7d1e150e110d3d1e0d0853181908531e13">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liping++Sun">Liping Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hua Xie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hua Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">College of Pharmacy, University of Chinese Academy of Sciences, Shanghai, China</div></div><span class="conrtib-corresp"><strong>*</strong>For H.X.: phone: +86-21-50805897; fax: 86-21-50805897; e-mail: <a href="/cdn-cgi/l/email-protection#6c041405092c1f050101420d0f420f02"><span class="__cf_email__" data-cfemail="81e9f9e8e4c1f2e8ececafe0e2afe2ef">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Xie">Hua Xie</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ao Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, and the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">College of Pharmacy, University of Chinese Academy of Sciences, Shanghai, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China</div></div><span class="conrtib-corresp"><strong>*</strong>For A.Z.: phone: +86-21-50806035; fax: 86-21-50806035; e-mail: <a href="/cdn-cgi/l/email-protection#dfbeb0a5b7beb1b89facb6b2b2f1bebcf1bcb1"><span class="__cf_email__" data-cfemail="bbdad4c1d3dad5dcfbc8d2d6d695dad895d8d5">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ao++Zhang">Ao Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7205-9202" title="Orcid link">http://orcid.org/0000-0001-7205-9202</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00441&amp;href=/doi/10.1021%2Facs.jmedchem.8b00441" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4608–4627</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 1, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 March 2018</li><li><span class="item_label"><b>Published</b> online</span>1 May 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00441</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4608%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYu%2BXue%252C%2BPeiran%2BSong%252C%2BZilan%2BSong%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D10%26contentID%3Dacs.jmedchem.8b00441%26title%3DDiscovery%2Bof%2B4%252C7-Diamino-5-%25284-phenoxyphenyl%2529-6-methylene-pyrimido%255B5%252C4-b%255Dpyrrolizines%2Bas%2BNovel%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4627%26publicationDate%3DMay%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00441"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3003</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00441" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Peiran&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Zilan&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Linjiang&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Ao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;4608-4627&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00441&quot;},&quot;abstract&quot;:&quot;An alternative medicinal chemistry approach was conducted on Bruton’s tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. 7S was identified as the most potent showing an IC50 value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to 1, 7S was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, 7S showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than 1 (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest 7S as a new BTK inhibitor worthy of further profiling.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00441&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00441" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00441&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00441" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00441&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00441" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00441&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00441&amp;href=/doi/10.1021/acs.jmedchem.8b00441" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00441" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00441" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26pmid%3D29715023%26genre%3Darticle%26aulast%3DXue%26date%3D2018%26atitle%3DDiscovery%2Bof%2B4%252C7-Diamino-5-%25284-phenoxyphenyl%2529-6-methylene-pyrimido%255B5%252C4-b%255Dpyrrolizines%2Bas%2BNovel%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D10%26spage%3D4608%26epage%3D4627%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/jmcmar.2018.61.issue-10/20180524/jmcmar.2018.61.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">An alternative medicinal chemistry approach was conducted on Bruton’s tyrosine kinase (BTK) inhibitor <b>1</b> (ibrutinib) by merging the pyrazolo[3,4-<i>d</i>]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. <b>7S</b> was identified as the most potent showing an IC<sub>50</sub> value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to <b>1</b>, <b>7S</b> was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, <b>7S</b> showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than <b>1</b> (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest <b>7S</b> as a new BTK inhibitor worthy of further profiling.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Bruton’s tyrosine kinase (BTK) protein is a nonreceptor tyrosine kinase belonging to the Tec kinase family (the other members are BMX, ITK, TEC, and TXK).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It plays a critical role in B-cell receptor (BCR) signaling by mediating B cell development and functioning. Therefore, dysregulation of BTK generally causes severe leukemias and B-cell related lymphomas.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> BTK is the upstream activator of multiple antiapoptotic signaling molecules and networks, and is primarily expressed in hematopoietic cells, particularly in B cells, but not in T cells or normal plasma cells.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The essential role of BTK in BCR signaling pathway and its restricted expression pattern warrant it as a viable and attractive therapeutic target for the treatment of B-cell malignancies.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The first-generation multitargeted BTK inhibitor ibrutinib<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> (<b>1</b>, PCI-32765) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) has been approved by FDA in 2013 to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and various clinical trials are ongoing for new indications.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Compound <b>1</b> is an irreversible inhibitor by covalently binding to Cys481 of BTK with its acrylamido moiety. In addition, <b>1</b> also irreversibly binds to other kinases such as epidermal growth factor receptor (EGFR), ITK, and TEC which might be attributed to the clinically observed adverse effects in ibrutinib-treated patients, including rash, diarrhea, arthralgias, atrial fibrillation, ecchymosis, and major hemorrhage.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Though it is not certain that the off-targets also contribute to the clinical antitumor efficacy of <b>1</b>, the objective of the second-generation BTK inhibitors is to achieve better BTK on-target selectivity to minimize the side effects.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, several compounds such as acalabrutinib<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (<b>2</b>, ACP-196), tirabrutinib<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (<b>3</b>, ONO/GS-4059), and spebrutinib<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (<b>4</b>, CC-292) are being extensively studied in the clinic both for evaluation of their therapeutical efficacies and for their safety profiles. Very recently, compound <b>2</b> possessing higher selectivity and an inhibitory effect against BTK received the FDA’s approval as a best-in-class treatment for CLL with a 100% response rate for patients positive for the 17p13.1 gene deletion—a subgroup of patients that typically results in a poor response to therapy and low expected clinical outcomes.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Intriguingly, compound <b>4</b>, another second-generation BTK inhibitor also irreversibly binding the Cys481 of BTK in high selectivity, shows a clinical activity (in particular, durability of response) inferior to that of <b>1</b> or <b>2</b>.<a onclick="showRef(event, 'ref7 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref11">(7,11)</a> In addition to covalent inhibitors, several noncovalent BTK inhibitors have also been reported.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> These noncovalent inhibitors could not form irreversible binding to BTK Cys481 because of the absence of the reactive binding group. However, they could target the binding pocket of inactive BTK conformations through conformational changes, which offers reversible interaction and binding to BTK.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Although the precise reason is unclear for the different clinical outcomes of these compounds, more diverse inhibitors with both novel structures and selective on-target binding profile are needed.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical BTK inhibitors <b>1</b>–<b>4</b> (A) and our design of new BTK inhibitors <b>I</b> and <b>II</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Rather than replacing the central hinge binder pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine template of <b>1</b> with other bicyclic (e.g., imidazo[1,5-<i>a</i>]pyrazin-8-amine in <b>2</b> and 6-amino-7<i>H</i>-purin-8(9<i>H</i>)-one in <b>3</b>) or monocyclic (e.g., 2,4-diaminopyrimidine in <b>4</b>) bioisosteres, we recently conducted a different medicinal chemistry approach by merging the pyrazolo[3,4-<i>d</i>]pyrimidine component and the piperidine ring of <b>1</b> into a tricyclic skeleton <b>I</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). Interestingly, during the synthesis of <b>I</b>, we found that a change of the cyclization reaction condition led to a different cyclization product <b>II</b>. Both compound series <b>I</b> and <b>II</b> contain brand new core structures that are rarely seen in other categories of therapeutical drugs.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Herein, we report the design, synthesis, and pharmacological evaluations of both series of compounds as novel BTK inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Drug Design</h3><div class="NLM_p">From the covalent docking model of <b>1</b> to BTK (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> the acrylamido moiety covalently binds to the Cys481 in the active site of BTK to achieve a potent and irreversible inhibition (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). In addition, the pyrazolo[3,4-<i>d</i>]pyrimidine backbone of <b>1</b> forms three critical hydrogen bonds with hinge residues Met477, Glu475, and Thr474, respectively, through an edge-to-face π–π interaction between the terminal phenyl group and Phe540 in the hydrophobic pocket. The pyrazolopyrimidine backbone of <b>1</b> proves to be effective in developing BTK inhibitors, and a dozen of mimetics (e.g., <b>2</b>–<b>4</b>) of this bicyclic framework have been reported.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A close examination of the binding mode of <b>1</b> with BTK reveals to us that there is a large space between the nearly orthogonal pyrazolyl and piperidyl groups, indicating that occupying this space with an appropriate ring might be well tolerated. Initially, we considered directly cyclizing the pyrazolyl and piperidyl moieties of <b>1</b> to form a tetracyclic artwork. However, considering the potential ring tension and the synthetic difficulty of the proposed tetracyclic backbone, a cutoff of the piperidyl ring is necessary, thus leading to our first design of the tricyclic compound series <b>I</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding modes of compounds <b>1</b> (A), <b>5</b> (B), and <b>7</b> (C) with BTK (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Preliminary Evaluation of Compounds <b>5</b>–<b>7</b></h3><div class="NLM_p">The tricyclic compound <b>5</b> was synthesized as a prototypic representative of compound series <b>I</b>. The tricycle pyrimido[5,4-<i>b</i>]pyrrolizine <b>7</b> (compound series <b>II</b>) was also obtained during optimization of the cyclization reaction condition. A docking of <b>5</b> to BTK was shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, in which the critical irreversible binding, key hydrogen bonds, and hydrophobic interaction as that shown in <b>1</b> were all retained. Interestingly, compound <b>7</b> bearing an exocyclic double bond also maintained the key interactions with BTK (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C), and the exocyclic double bond had no significant contacts in the catalytic domain. This analysis suggested that compounds <b>5</b> and <b>7</b> might be potent BTK inhibitors.</div><div class="NLM_p">BTK inhibitory activity of compounds <b>5</b> and <b>7</b> were evaluated by using well-established ELISA assays. The saturated compound <b>6</b> was prepared as a comparison, and compound <b>1</b> (ibrutinib) was included as a positive control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, compounds <b>5</b> and <b>7</b> bearing an acrylamido moiety were highly potent BTK inhibitors with IC<sub>50</sub> values of 5.3 nM and 2.8 nM, respectively, which were only 13-fold and 7-fold less potent than <b>1</b>. Compound <b>6</b> bearing a nonreactive propylamido moiety was approximately 1040-fold less potent (IC<sub>50</sub> of 417.4 nM) than <b>1</b>. The significant discrepancy in biochemical activity between <b>5</b> and <b>6</b> illustrated the necessity of the acrylamido warhead for irreversible covalent binding with BTK Cys481. The effects of compound <b>7</b> against BTK<sup>C481S</sup> mutant were further examined (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Compared to the high potency against wild-type BTK, compound <b>7</b> exhibited 165-fold reduction of potency against BTK<sup>C481S</sup> (IC<sub>50</sub> of 463.6 vs 2.8 nM). These results suggested that the new tricyclic compounds <b>5</b> and <b>7</b> were potent BTK inhibitors and might covalently bind to the Cys481 leading to irreversible inhibition on BTK kinase activity, a similar interaction profile to that of <b>1</b>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterizations of compounds <b>5</b>–<b>7</b> as potent BTK inhibitors. (A) Chemical structures of <b>5</b>–<b>7</b>. (B) In vitro kinase inhibitory activities of compounds against wild-type BTK. (C) In vitro kinase inhibitory activities of compounds <b>7</b> and <b>1</b> against BTK<sup>C481S</sup> mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Kinase Selectivity Study of Compounds <b>5</b> and <b>7</b></h3><div class="NLM_p">To determine possible off-targets, we further analyzed the kinase selectivity of the two new BTK inhibitors <b>5</b> and <b>7</b> by the KINOMEScan screening platform.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Both compounds were tested against a panel of 468 kinases and mutants at 1 μM concentration, and the results were shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Compound <b>7</b> was found to possess a better selectivity (S-score (1) = 0.007), whereas the S(1) value of <b>5</b> was 0.027. Not surprisingly, the major off-targets of both compounds were those kinases bearing a cysteine residue in the ATP binding pocket similar to BTK, which could be covalently bound by the acrylamido warhead, including BLK, EGFR, EebB4, TEC, and so on. More specifically, compound <b>7</b> had only three major off-targets (BLk, ErbB4, MEK) with a percent control number less than 1 at 1 μM concentration, a selectivity profile much better than that of compounds <b>5</b> and <b>1</b>.<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Human kinome wide selectivity profiling of compounds <b>5</b> and <b>7</b> in DiscoveRx KINOMEScan screening platform. Measurements were performed at 1 μM concentration of the compounds. Upper panel: TREE<i>spot</i> interaction maps for <b>5</b> and <b>7</b> in 468 kinase targets. Lower panel: S-scores of <b>5</b> and <b>7</b> with percent control numbers less than 35, 10, and 1, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure Optimization on Lead Compound <b>7</b></h3><div class="NLM_p">In view of the structural novelty, high potency, and better kinase selectivity profile, we selected compound <b>7</b> as our tricyclic lead BTK inhibitor for further structural optimization. First, to identify the optimal covalent warhead binding to BTK Cys481 residue, a panel of reactive acrylamido groups was tested (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). First, we inserted variant amino acid moieties into the acrylamido fragment, and the corresponding compounds <b>8</b>–<b>11</b> showed reduced potencies against BTK. Compared to compound <b>7</b>, insertion of smaller amino acid moieties such as 2-aminoacetyl (<b>8</b>, IC<sub>50</sub> of 23.6 nM), 2-aminopropanoyl (<b>9</b>, IC<sub>50</sub> of 40.1 nM), or 1-aminocyclopropanecarbonyl (<b>10</b>, IC<sub>50</sub> of 23.8 nM) led to a 8–14-fold loss of potency, and insertion of a longer amino acid moiety such as 3-aminopropanoyl (<b>11</b>, IC<sub>50</sub> of 725.2 nM) significantly reduced the inhibitory potency. Substitution on the terminal vinyl carbon with a dimethylaminomethyl yielded compound <b>12</b>, which retained high potency with an IC<sub>50</sub> value of 4.3 nM. Notably, replacing the acrylamido moiety in <b>7</b> with a but-2-ynamido moiety provided compound <b>13</b> showing an IC<sub>50</sub> value of 2.1 nM, a potency even higher than that of <b>7</b> (IC<sub>50</sub> of 2.8 nM). Compound <b>14</b> lacking the acryloyl warhead completely lost the potency (IC<sub>50</sub> > 1000 nM), whereas saturation of the acrylamido with nonreactive propionyl moiety led to 22-fold reduction of potency (<b>15</b>, IC<sub>50</sub> of 62.6 nM). These results further confirmed that the existence of a Michael acceptor warhead was essential for BTK’s covalent binding, and the but-2-ynamido (<b>13</b>, IC<sub>50</sub> of 2.1 nM) was slightly better than the prototypic acrylamido moiety (<b>7</b>, IC<sub>50</sub> of 2.8 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro BTK Inhibition of Compounds Bearing Different Covalent or Noncovalent Reactive Groups</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Chiral Resolution of Potent BTK Inhibitors <b>5</b>, <b>7</b>, and <b>13</b></h3><div class="NLM_p">Since compound <b>1</b> is an optically pure <i>R</i>-enantiomer in the stereogenic carbon center, its <i>S</i>-enantiomer as well as the racemate are less potent.<a onclick="showRef(event, 'cit5a'); return false;" href="javascript:void(0);" class="ref cit5a">(5a)</a> To determine where this was also the case in our new tricyclic BTK inhibitors, the <i>R</i>- and <i>S</i>-enantiomers of the three potent racemic compounds <b>5</b>, <b>7</b>, and <b>13</b> were prepared and tested. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, enantiomers <b>5R</b> and <b>5S</b> showed nearly identical IC<sub>50</sub> values (3.0 vs 2.8 nM). Surprisingly, significant discrepancy was observed between the two enantiomers of <b>7</b> and <b>13</b> both bearing the pyrimido[5,4-<i>b</i>]pyrrolizine framework. In both cases, the <i>S</i>-enantiomers were more potent than their corresponding <i>R</i>-enantiomers. Both <b>7S</b> and <b>13S</b> showed high potency with an identical IC<sub>50</sub> value of 0.4 nM, which was equal to that of <b>1</b> (IC<sub>50</sub> of 0.4 nM), whereas the IC<sub>50</sub> values of <i>R</i>-enantiomers <b>7R</b> and <b>13R</b> were 6.1 and 3.3 nM, respectively. The similar biochemical activity of the enantiomers <b>5S</b> and <b>5R</b> on BTK binding is likely ascribed to the fact that the newly formed piperidine ring in <b>5</b> could adapt a configuration change upon covalently binding to the active site of BTK. However, the newly formed pyrrole ring in <b>7</b> and <b>13</b> has more ring and steric strain that is disadvantageous for ring tortuosity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro BTK Inhibition of the Stereoisomers of Potent Compounds <b>5</b>, <b>7</b>, and <b>13</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0015.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacokinetic (PK) Parameters of the Selected BTK Inhibitors <b>7S</b> and <b>13S</b></h3><div class="NLM_p">Since both <b>7S</b> and <b>13S</b> showed high potencies against BTK kinase, they were selected for pharmacokinetic study in rats following intravenous (1 mg/kg) and oral (3 mg/kg) administration. As a comparison, <b>1</b> was also tested in the same conditions. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, both <b>7S</b> and <b>13S</b> have similar half-lives (<i>T</i><sub>1/2</sub> = 0.57 and 0.54 h, respectively), which were slightly longer than that of <b>1</b> (<i>T</i><sub>1/2</sub> = 0.42 h). Meanwhile, better plasma exposure after oral administration was observed for both tricyclic compounds, and the AUC<sub>0-∞</sub> values for <b>7S</b> and <b>13S</b> were 4- and 10-fold higher than that of <b>1</b>, respectively. The same trend was observed in their <i>C</i><sub>max</sub> values. In addition, both <b>7S</b> and <b>13S</b> showed lower clearances than <b>1</b>. Finally, the oral bioavailabilities of <b>7S</b> and <b>13S</b> were calculated as 18.3% and 35.8%, respectively, which were much higher than that of <b>1</b> (<i>F</i> = 4.00%).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PK Parameters of the New BTK Inhibitors <b>7S</b> and <b>13S</b> in Rats<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">iv (1 mg/kg)</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po (3 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub><b>ss</b></sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub><b>0-∞</b></sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">61.2</td><td class="colsep0 rowsep0" align="char" char=".">1838</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7S</b></td><td class="colsep0 rowsep0" align="char" char=".">46.3</td><td class="colsep0 rowsep0" align="char" char=".">1299</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td><td class="colsep0 rowsep0" align="char" char=".">223</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">211</td><td class="colsep0 rowsep0" align="char" char=".">18.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13S</b></td><td class="colsep0 rowsep0" align="char" char=".">32.8</td><td class="colsep0 rowsep0" align="char" char=".">1390</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">340</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">557</td><td class="colsep0 rowsep0" align="char" char=".">35.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are the average of three determinations. Vehicle: DMSO, Tween 80, normal saline. CL, clearance; <i>V</i><sub>ss</sub>, volume of distribution; <i>T</i><sub>1/2</sub>, half-life; <i>C</i><sub>max</sub>, maximum concentration; <i>T</i><sub>max</sub>, time of maximum concentration; AUC<sub>0-∞</sub>, area under the plasma concentration time curve; <i>F</i>, oral bioavailability.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Metabolic Stability Study of the Selected BTK Inhibitors <b>7S</b> and <b>13S</b></h3><div class="NLM_p">To evaluate the metabolic stability of the new tricyclic BTK inhibitors <b>7S</b> and <b>13S</b>, we investigated the potential metabolites of both compounds by incubating with liver microsomes of different species (mouse, rat, and human) for 3 h. The major metabolites were tested by LC/MS (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, Table S1). Both compounds showed moderate to good stability with similar metabolic products in the liver microsomes. Compound <b>7S</b> was more stable in mouse liver microsomes (MLM) than in human liver microsomes (HLM) and rat liver microsomes (RLM). Differently, compound <b>13S</b> was much more stable in HLM and MLM, but not stable in RLM. In general, the major metabolic pathway for both compounds was the <i>para</i>-oxidation of the phenyl group in the diphenyl ether component leading to <i>para</i>-hydroxylated compound <b>M-1</b>, accounting for 16.5% and 18.8%, respectively, of the total metabolites (including parent compound <b>M-0</b>) in HLM (<a class="ref internalNav" href="#notes-2" aria-label="Table S1">Table S1</a>). In addition, substantial dihydroxylation occurred in both the vinyl (<b>7S</b>) and ethynyl (<b>13S</b>) moieties across the three liver microsomes. The proposed metabolic pathways of both compounds were shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A, B) Metabolic study of compounds <b>7S</b> and <b>13S</b> in liver microsomes of different species.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Further Modification of Compound <b>7S</b></h3><div class="NLM_p">Since the metabolic stability study in liver microsome revealed that the most active metabolic site of compound <b>7S</b> might be the <i>para</i>-position of the terminal phenyl group. Therefore, two approaches were conducted to eliminate or ultimately reduce the <i>para</i>-phenyl oxidative metabolism (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). First, we introduced a small series of substituents to the <i>para</i>-position of the terminal phenyl to block the hydroxylation liability. It was found that all the substituents, including -<i>t</i>-Bu (<b>16</b>), -F (<b>17</b>), -CF<sub>3</sub> (<b>18</b>), and -OCF<sub>3</sub> (<b>19</b>) groups, appended in the <i>para</i>-position caused a 5–19-fold decrease of potency, compared to that of <b>7S</b>. The reduced potency was likely due to the steric hindrance in the hydrophobic binding pocket. In the meantime, replacement of the terminal phenoxy fragment with various <i>N</i>-aryl or <i>N</i>-arylmethyl carbamic groups was conducted to block the active metabolic site. To our delight, compared to <b>7S</b>, compound <b>20</b> bearing a pyridie-2-ylcarbamic group showed compatible biochemical potency against BTK with an IC<sub>50</sub> value of 0.5 nM. Compound <b>21</b> bearing an additional trifluoromethyl group also retained high potency of 0.8 nM. Replacing the terminal phenoxy group of <b>7S</b> with (1-(pyridin-2-yl)ethyl)carbamic moiety significantly reduced the potency (<b>22</b>, IC<sub>50</sub> of 50.4 nM), whereas slightly lower potency was observed for compounds <b>23</b> and <b>24</b>, both bearing a benzylcarbamic moiety and showing IC<sub>50</sub> values of 3.1 nM and 4.3 nM, respectively.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro BTK Inhibition of Compounds Modified in Terminal Phenyl to Block the <i>para</i>-Oxidative Metabolism</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0016.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0017.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div><div></div></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Antiproliferative Effects of Compounds <b>7S</b>, <b>20</b>, and <b>1</b></h3><div class="NLM_p">Since the optimized compound <b>20</b> showed similar high potency against BTK as that of the lead compound <b>7S</b> and the approved drug <b>1</b>, both <b>7S</b> and <b>20</b> were selected for an antiproliferative effect study in the B-cell lymphoma (Ramos and TMD8) cells. Compound <b>1</b> was also tested as a comparison. Both Ramos and TMD8 cells are B-cell lymphoma cell lines expressing BTK protein, but the Ramos cells are not strongly depended on it, whereas the survival of TMD8 cells is strongly dependent on the expression of BTK protein.<a onclick="showRef(event, 'cit4b'); return false;" href="javascript:void(0);" class="ref cit4b">(4b)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, compounds <b>7S</b> and <b>20</b> suppressed the proliferation of Ramos cells in the micromolar range with IC<sub>50</sub> values of 5.03 μM and 14.3 μM, respectively, whereas the approved drug <b>1</b> showed an IC<sub>50</sub> value of 0.92 μM. This result confirmed that <b>1</b> was a nonselective BTK inhibitor and its antitumor activity was a consequence of multiple kinase inhibition. The lower potency of the new inhibitors <b>7S</b> and <b>20</b> indicated that these new tricyclic compounds were more BTK-selective. This analysis was further confirmed by the high antiproliferative potency against the BTK highly sensitive TMD8 cells. All three compounds <b>1</b>, <b>7S</b>, and <b>20</b> showed low nanomolar potency with IC<sub>50</sub> values of 10 nM, 16 nM, and 4 nM, respectively, in this cell line.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Target Inhibition and Antiproliferative Effects of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char="±">BTK</th><th class="colsep0 rowsep0" align="center" char="±">Ramos</th><th class="colsep0 rowsep0" align="center" char="±">TMD8</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0004 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">0.92 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.010 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7S</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0004 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">5.03 ± 0.85</td><td class="colsep0 rowsep0" align="char" char="±">0.016 ± 0.010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0005 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">14.3 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div></div><div class="NLM_p last">From the results above, both new inhibitors <b>7S</b> and <b>20</b> showed high potency and selectivity against BTK, especially for compound <b>20</b>. Unfortunately, further pharmacokinetic study on <b>20</b> showed a lower oral bioavailability of 8.24% (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, Table S2). Taken together, compound <b>7S</b> showed overall optimal drug candidacy and was elected for further profiling.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Covalent Docking Mode of 7S with BTK</h3><div class="NLM_p">Similar to binding mode of compound <b>7</b> with BTK in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, the specific <i>S</i>-enantiomer <b>7S</b> could covalently bind to BTK Cys481. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>7S</b> overlapped well with <b>1</b>, including the bicyclic skeleton as well as the hydrophobic moiety. The sulfhydryl of Cys481 rotated about 68° to adapt the newly formed covalent bond between the acrylamido moiety of <b>7S</b> and BTK Cys481. Critical hydrogen bonds with hinge residues Met477, Glu475, and Thr474 were also observed with distances of 2.0, 1.9, and 2.8 Å, respectively. In addition, there is a π–π interaction between the terminal phenyl group and Phe540.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Covalent docking mode of compound <b>7S</b> (green) with BTK (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>) overlapping with <b>1</b> (purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Kinase Selectivity Profile of <b>7S</b></h3><div class="NLM_p">On the basis of the KINOMEScan screening results of the racemic compound <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), we further tested the biochemical activity of compound <b>7S</b> against a panel of 14 kinases. Similar to <b>1</b>, the major off-target kinases of <b>7S</b> were those with cysteine residue in the ATP binding pocket, which could be irreversibly bound by the covalent reactive group (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). As such, compound <b>7S</b> showed a high potency against EGFR (IC<sub>50</sub> of 1.3 nM), but variant potency against the other members of the Tec kinase family with IC<sub>50</sub> values of 174.1, 15.1, 1.4, and 2.5 nM for BMX, ITK, TEC, and TXK, respectively. Although the overall selectivity was similar to <b>1</b>, <b>7S</b> showed greater BTK selectivity than <b>1</b> against BMX (174.1 vs 5.8 nM), RET (20.3 vs 5.2 nM), and ErbB2 (23.2 vs 1.5 nM). It was not clear whether such difference in kinase selectivity between <b>7S</b> and <b>1</b> was beneficial to the antitumor efficacy or clinical safety; a careful balance of the clinical outcomes should be taken if compound <b>7S</b> finally proceeds to clinical trials.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Selectivity Profile of Compound <b>7S</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><b>7S</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="left">0.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB4</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.8 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">1.4 ± 0.6</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.5</td><td class="colsep0 rowsep0" align="left">3.0 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="left">15.1 ± 3.2</td><td class="colsep0 rowsep0" align="left">13.9 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="left">20.3 ± 6.6</td><td class="colsep0 rowsep0" align="left">5.2 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB2</td><td class="colsep0 rowsep0" align="left">23.2 ± 1.5</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-3</td><td class="colsep0 rowsep0" align="left">55.0 ± 11.7</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX</td><td class="colsep0 rowsep0" align="left">174.1 ± 93.3</td><td class="colsep0 rowsep0" align="left">5.8 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="left">214.5 ± 126.0</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPH-A2</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF1R</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Effects of Compound <b>7S</b> on TMD8 Cells</h3><div class="NLM_p">BTK plays an imperative role in BCR signaling pathway, which is relevant to several severe leukemias and lymphomas. BCR is first activated by CD79, which causes activation of upstream kinases, such as spleen tyrosine kinase (SYK). Then BTK is recruited to cell membrane and phosphorylated in its SH2 domain. The activated BTK then phosphorylates its substrate phospholipase γ2 (PLCγ2), leading to activation of the downstream signaling pathways, such as NF-κB and STAT3.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In the BTK-dependent diffuse large B-cell lymphoma (DLBCL) TMD8 cells, both compound <b>7S</b> and <b>1</b> were found to significantly inhibit the autophosphorylation of BTK at the Y223 site. Particularly, <b>7S</b> showed a dose-dependent inhibition with an IC<sub>50</sub> value less than 10 nM. Furthermore, <b>7S</b> inhibited downstream phosphorylation of Y759 of PLCγ2 comparable to that of <b>1</b> at 1 μM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compound <b>7S</b> on TMD8 cells. (A) Inhibitory activity of <b>7S</b> on BTK and downstream signaling pathway in cells. Cells were starved in serum-free medium before treated with the indicated concentrations of compound <b>7S</b> or <b>1</b> for 4 h and stimulated by anti-IGM. (B) Washout experiment of <b>7S</b> in TMD8 cells. (C) Effects of <b>7S</b> on cell cycle in TMD8 cells. (D) <b>7S</b> induced apoptosis of TMD8 cells. Data are shown as mean ± SD. Each experiment was conducted independently three times. *<i>P</i> < 0.05, **<i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Meanwhile, we carried out a washout experiment to further confirm the irreversibility of compounds <b>7S</b> and <b>1</b> on the inhibition of BCR signaling pathway in TMD8 cells (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). After 2 h exposure of <b>7S</b> and <b>1</b> at 1 μM, the cells were washed with PBS and collected in 0, 2, 4, 8, 12, and 24 h, and the phosphorylated levels of BTK at Y223 were detected. The results showed that <b>7S</b> treatment for 2 h completely inhibited the phosphorylation of BTK at Y223, and the inhibition could be observed even after 24 h washout. All these results suggested a strong irreversible inhibition of <b>7S</b> on BTK, a profile similar to that of compound <b>1</b>.</div><div class="NLM_p">The effects of <b>7S</b> on the cell cycle progression in TMD8 cells were investigated as well. After 48 h treatment with TMD8 cells, <b>7S</b> was found to significantly arrest cell cycle progression at G1 phase in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). Exposure to 1 nM of <b>7S</b> arrested 57% cells occupying the G1 phase, compared with 51% of control cells. Approximately 77% of cells was arrested in G1 phase when the concentration reached to 100 nM. We then proceeded to test the effects of <b>7S</b> on apoptosis in TMD8 cells. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D, <b>7S</b> triggered concentration-dependent apoptosis of the cells with ratios of 40%, 49%, and 79% at concentrations of 10 nM, 100 nM, and 1000 nM, respectively, compared with 11% in untreated control cells.</div><div class="NLM_p last">Together, these results demonstrated that <b>7S</b>, as a new inhibitor of BTK, induced apoptosis and G1 phase cell cycle arrest, thus suppressing the growth of cancer cells.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Tumor Growth Inhibition of <b>7S</b> in the TMD8 Xenograft Model</h3><div class="NLM_p">In view of the promising in vitro profile of the new BTK inhibitor <b>7S</b>, we then evaluated its antitumor activity in vivo in female CB-17 SCID nude mice bearing human TMD8 tumor cells. Both compounds <b>7S</b> and <b>1</b> were administered orally (po) once daily (QD) for 13 consecutive days until the vehicle group had to be euthanized due to the tumor burden. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, oral administration of <b>7S</b> at 5 mg/kg showed minor antitumor efficacy with a relative tumor volume (RTV) of 11.1. However, at a higher dose of 15 mg/kg QD, compound <b>7S</b> significantly suppressed the tumor growth with RTV of 5.3. The reference compound <b>1</b> showed a RTV of 6.6 at the dose of 25 mg/kg QD. The smaller RTV rate (5.3 vs 6.6) and lower dosage (15 vs 25 mg/kg) of <b>7S</b> over <b>1</b> indicated that compound <b>7S</b> had higher antitumor efficacy in vivo. Further, the significant suppression of both <b>7S</b> and <b>1</b> on tumor growth was maintained to 17 days when the lower dosage group of <b>7S</b> (5 mg/kg) had to be euthanized. In all four groups, the mice slightly gained weight after treatment, and no significant weight fluctuations were observed during the course (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo TMD8 xenograft model study of compound <b>7S</b> and <b>1</b>. (A) The tumor growth curve of four groups, including vehicle control, <b>1</b> (25 mg/kg, QD), <b>7S</b> (5 mg/kg, QD), and <b>7S</b> (15 mg/kg, QD). The vehicle group was euthanized on day 13 of treatment, and the other three groups were executed on day 17 of treatment. (B) The body weights of the group mice over time. (C) Inhibition of target (BTK and PLCγ2) activation by <b>7S</b> in tumors. (D) Immunohistochemical analysis of <i>K</i><sub>i</sub>-67 in tumor tissues. *<i>P</i> < 0.05 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We also elucidated the effects of <b>7S</b> on target inhibition in tumor by using Western blot analysis. The data show a significant reduction of <i>p</i>-BTK expression upon D-39 treatment, accompanied by a decrease of <i>p</i>-PLCγ2 expression (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). The expression of <i>K</i><sub>i</sub>-67, a proliferation marker in tumor,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> was evaluated by using immunohistochemistry and H&E staining. A significant decrease of <i>K</i><sub>i</sub>-67 expression was observed in <b>7S</b> treatment group compared to the control group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D). These results clearly demonstrated that <b>7S</b> efficiently inhibited the activation and downstream signaling transduction of BTK and thus suppressed the tumor growth.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25013" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25013" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of Tricyclic Compounds</h3><div class="NLM_p">Pyrimido[5,4-<i>b</i>]indolizine compounds <b>5</b> and <b>6</b> were prepared as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis was started from the <i>O</i>-esterification of racemic <i>N</i>-protected alcohol <b>25</b> with methanesulfonyl chloride (MesCl) to generate the intermediate <b>26</b> in 85% yield. Substitution of 4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine with aminoalcohol <b>26</b> delivered pyrrolo[2,3-<i>d</i>]pyrimidine <b>27</b> in 74% yield. Ammonolysis of <b>27</b> with ammonium hydroxide in a seal tube resulted in compound <b>28</b> in 75% yield. Pd-catalyzed Suzuki–Miyaura coupling of iodide <b>28</b> with 4-phenoxyphenylboronic acid afforded diphenyl ether <b>29</b> in 71% yield. Bromination of ether <b>29</b> with <i>N</i>-bromo succinimide (NBS) afforded bromide <b>30</b> in 84% yield. Brown hydroboration of <b>30</b> in the terminal double bond followed by intramolecular Suzuki–Miyaura coupling using PdCl<sub>2</sub>dppf catalyst delivered tricyclic compound <b>31</b> in 49% overall yield. <i>N</i>-Deprotection with trifluoroacetic acid (TFA) followed by acylation with acrylic anhydride or carboxylic acid afforded compound <b>5</b> or <b>6</b> in 58% and 73% yields, respectively.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) MesCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 85%; (b) K<sub>2</sub>CO<sub>3</sub>, DMF, N<sub>2</sub>, 55 °C, 74%; (c) NH<sub>3</sub>·H<sub>2</sub>O, 1,4-dioxane, 120 °C, seal tube, 75%; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 90 °C, 71%; (e) NBS, DMF, rt, 84%; (f) (1) 9-BBN, anhydrous THF, N<sub>2</sub>, 0 °C to rt; (2) PdCl<sub>2</sub>dppf, NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 49% (two steps); (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 58% (two steps); (i) propanoic acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 73% (two steps).</p></p></figure><div class="NLM_p">It has to be mentioned that during the preparation of tricyclic compound <b>31</b>, the yield was highly dependent on the quality of boronation agent 9-borabicyclo[3.3.1]nonane (9-BBN). Lower quality of 9-BBN led to both the tricyclic <b>31</b> and <b>33</b>. After optimization of the coupling conditions, we found that compound <b>33</b> could be conveniently prepared in 88% yield through direct intramolecular Heck reaction of the precursor <b>30</b> under the catalysis of Pd(PPh<sub>3</sub>)<sub>4</sub> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). After removal of the <i>N</i>-Boc protecting group of <b>33</b> with TFA, subsequent acylation with an appropriate acid or anhydride afforded the corresponding acylamides <b>7</b>–<b>13</b> and <b>15</b> in 45–91% yields.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>7</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 88%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 98%; (c) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 45% (two steps); (d) R<sup>4</sup>-COOH, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 66–91% (two steps).</p></p></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis of Chiral Compounds</h3><div class="NLM_p">The optically pure isomers of compounds <b>5</b>, <b>7</b>, and <b>13</b> were prepared from the <i>R</i>- or <i>S</i>-configurated isomer of <b>25</b>, which was obtained by following a literature procedure.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, phthalimide was treated with racemic 2-vinyloxirane using Pd<sub>2</sub>(C<sub>3</sub>H<sub>5</sub>)<sub>2</sub>Cl<sub>2</sub> and (<i>S</i>,<i>S</i>)-DACH-naphthyl Trost ligand leading to the <i>R</i>-configurated intermediate <b>34R</b> in a highly regio- and enantioselective fashion (yield 92%, <i>ee</i> 98%). The absolute configuration of this intermediate was confirmed by X-ray diffraction analysis (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, Figure S1, Table S3). Subsequent treatment with CH<sub>3</sub>NH<sub>2</sub> in open air in 60 °C followed by <i>N</i>-Boc protection delivered <b>25R</b>, the key intermediate for the preparation of optically pure <b>5R</b>, <b>7R</b> and <b>13R</b>. Similarly, the same reaction sequence using (<i>R</i>,<i>R</i>)-DACH-naphthyl Trost ligand afforded the <i>S</i>-configured isomer <b>25S</b>, the key intermediate for <b>5S</b>, <b>7S</b>, <b>13S</b>, and <b>16</b>–<b>24</b>. Although we failed to obtain the X-ray analysis of these final compounds, a key precursor <b>30S</b> from <b>25S</b> was successfully crystallized and its X-ray analysis confirmed the absolute configuration (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, Figure S2, Table S4).</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the <i>R</i>- or <i>S</i>-Isomers of Compounds <b>5</b>, <b>7</b> and <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(C<sub>3</sub>H<sub>5</sub>)<sub>2</sub>Cl<sub>2</sub>, (<i>S</i>,<i>S</i>)-DACH-naphthyl Trost ligand for <b>34R</b> and (<i>R</i>,<i>R</i>)-DACH-naphthyl Trost ligand for <b>34S</b>, Na<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, N<sub>2</sub>, rt, yield 92%, <i>ee</i> 98%; (b) 1) NH<sub>2</sub>CH<sub>3</sub>, open to air, 60 °C; 2) Boc<sub>2</sub>O, NaHCO<sub>3</sub>, ethyl acetate, 88% (two steps).</p></p></figure><div class="NLM_p">The synthesis of the <i>S</i>-configured compounds <b>16</b>–<b>24</b> was shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Suzuki–Miyaura coupling of the <i>S</i>-configured iodide <b>28S</b>, which was prepared from <b>25S</b>, with aryl boronates <b>35a</b>–<b>i</b> under Pd(PPh<sub>3</sub>)<sub>4</sub> catalysis provided compounds <b>36a</b>–<b>i</b> in 61–85% yields. Bromination of <b>36a</b>–<b>i</b> followed by intermolecular Heck reaction with Pd(PPh<sub>3</sub>)<sub>4</sub> or PdCl<sub>2</sub>dppf yielded tricyclic compounds <b>38a</b>–<b>i</b> in 53–81% yields. Removal of the <i>N</i>-Boc protecting group followed by acylation with acrylic anhydride provided the corresponding compounds <b>16</b>–<b>24</b> in 45–79% overall yields.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Chiral Compounds <b>16</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, N<sub>2</sub>, 90 °C, 61–85%; (b) NBS, DMF, rt, 70–77%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (for <b>16</b>-<b>19</b>) or PdCl<sub>2</sub>dppf (for <b>20</b>-<b>24</b>), NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 53–81%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 45–79% (two steps).</p></p></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, using a structure-based drug design strategy, a new medicinal chemistry approach was conducted on the BTK inhibitor <b>1</b> (ibrutinib) by merging the pyrazolo[3,4-<i>d</i>]pyrimidine component and the piperidine ring <b>1</b> into a tricyclic skeleton. Two series of compounds were prepared, and their binding model, biochemical activity, as well as effects of the stereochemistry on BTK were determined. Subsequent structural optimization both focusing on the reactive acrylamido group as the covalent binder to the BTK Cys481 residue and on the metabolic active site were conducted leading to the tricyclic compound <b>7S</b> as the most potent and orally available BTK inhibitor. Compound <b>7S</b> has a biochemical IC<sub>50</sub> value of 0.4 nM against BTK and antiproliferative potency of 16 nM against BTK-dependent TMD8 cells. Compared to the multikinase inhibitor <b>1</b>, the new inhibitor <b>7S</b> is slightly more selective against BTK, and showed strong inhibition on the BCR signaling pathway in TMD8 cells. Significant cell cycle arrest in G0-G1 phase and does-dependent inducing of apoptosis were observed as well. In the TMD8 cell-derived xenograft model, <b>7S</b> shows an RTV of 5.3 at a dose of 15 mg/kg QD that is more efficacious than compound <b>1</b> (RTV 6.6) at a higher dose of 25 mg/kg QD. In view of the novel tricyclic structure of <b>7S</b> together with its encouraging in vitro and in vivo properties, this compound is worthy of further profiling as a new BTK inhibitor. Currently, an early preclinical study on this compound has been undergoing for potential treatment of B-cell related lymphomas.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Chemistry</h3><div class="NLM_p">All reactions were performed in glassware containing a Teflon coated stir bar. Commercial solvents and reagents were obtained from sources Adamas-beta, Acros Organics, Strem Chemicals, Alfa Aesar, J&K, TCI, and Laajoo and used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded with a Varian-MERCURY Plus-300 MHz NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>), deuterium chloroform (CDCl<sub>3</sub>) or CDCl<sub>3</sub> + deuterium methanol (CD<sub>3</sub>OD). Chemical shifts (δ) were reported in ppm downfield from an internal TMS standard. Low- and high-resolution mass spectra were obtained in the ESI mode. Flash column chromatography on silica gel (200–300 mesh) was used for the routine purification of reaction products. The column outputs were monitored by TLC on silica gel (200–300 mesh) precoated on glass plates (15 mm × 50 mm), and spots were visualized by UV light at 254 or 365 nm. Some outputs were colored by basic KMnO<sub>4</sub> solution. Compounds <b>25</b>, <b>25S</b>, <b>25R</b>, and <b>35a</b>-<b>i</b> were prepared according to corresponding literature procedures.<a onclick="showRef(event, 'cit20f ref24 ref25'); return false;" href="javascript:void(0);" class="ref cit20f ref24 ref25">(20f,24,25)</a> HPLC analysis was conducted for all biologically evaluated compounds on an Agilent Technologies 1260 series LC system (Agilent ChemStation Rev.A.10.02; ZORBAX Eclipse XDB-C18, 4.6 mm × 150 mm, MeOH/H<sub>2</sub>O, rt; CHIRALPAK AD-H, 4.6 mm × 250 mm, <i>n</i>-hexane/<i>i</i>-PrOH or <i>n</i>-hexane/<i>i</i>-PrOH (with 0.1% (v/v) diethylamine), rt; CHIRALPAK IG, 4.6 mm × 150 mm, MeOH/diethylamine, 35 °C; CHIRALPAK IE, 4.6 mm × 250 mm, <i>n</i>-hexane/EtOAc, rt; CHIRALPAK AYH, 4.6 mm × 150 mm, <i>n</i>-hexane/EtOH/diethylamine, 35 °C) with ultraviolet wavelengths in UV 254 to determine the chemical purity and optical purity. The purities of all biologically evaluated compounds were above 95%.</div><div class="NLM_p">Compounds <b>5R</b> and <b>5S</b> were prepared following the synthetic procedure for racemate <b>5</b> from their corresponding enantiomeric precursors.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(4-Amino-5-(4-phenoxyphenyl)-6,7,8,9-tetrahydropyrimido[5,4-<i>b</i>]indolizin-8-yl)acrylamide (<b>5</b>)</h4><div class="NLM_p">To a solution of compound <b>31</b> (472 mg, 1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added trifluoroacetic acid (1.9 mL) dropwise. The mixture was stirred at room temperature for 3 h and then quenched with saturated NaHCO<sub>3</sub> solution dropwise until neutral. After extraction with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL), the combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product <b>32</b> was given as a yellowish solid and could be used in the next step without further purification.</div><div class="NLM_p last">To a solution of compound <b>32</b> in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added acrylic anhydride (115 μL, 1.0 mmol) and Et<sub>3</sub>N (154 μL, 1.1 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. After quenching with water (5 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL), the organic phase was separated and washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>5</b> (248 mg, 58.3%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+CD<sub>3</sub>OD) δ 8.07 (s, 1H), 7.32 (t, <i>J</i> = 8.0 Hz, 2H), 7.26 (d, <i>J</i> = 8.7 Hz, 2H), 7.09 (t, <i>J</i> = 7.4 Hz, 1H), 7.02 (d, <i>J</i> = 8.6 Hz, 4H), 6.31–6.07 (m, 2H), 5.61 (dd, <i>J</i> = 10.0, 1.8 Hz, 1H), 4.53–4.43 (m, 1H), 4.38 (dd, <i>J</i> = 12.3, 5.2 Hz, 1H), 3.82 (dd, <i>J</i> = 12.2, 8.4 Hz, 1H), 2.99–2.84 (m, 2H), 2.20–2.07 (m, 1H), 1.91–1.75 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 166.13, 156.86, 156.47, 156.03, 149.99, 148.89, 131.08 (2C), 130.30, 130.07, 129.86 (2C), 128.29, 126.94, 123.80, 119.35 (2C), 118.67 (2C), 110.32, 101.87, 45.28, 44.20, 26.61, 20.16. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 426.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>, 426.1925; found, 426.1923.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-<i>N</i>-(4-Amino-5-(4-phenoxyphenyl)-6,7,8,9-tetrahydropyrimido[5,4-<i>b</i>]indolizin-8-yl)acrylamide (<b>5R</b>)</h4><div class="NLM_p last">White solid. Yield 236 mg, 55.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.21 (s, 1H), 7.42–7.32 (m, 4H), 7.16 (t, <i>J</i> = 7.5 Hz, 1H), 7.09 (d, <i>J</i> = 8.3 Hz, 4H), 6.41–6.10 (m, 3H), 5.70 (d, <i>J</i> = 9.8 Hz, 1H), 4.94 (s, 2H), 4.70 (s, 1H), 4.42 (dd, <i>J</i> = 13.3, 5.2 Hz, 1H), 4.11 (dd, <i>J</i> = 13.1, 6.0 Hz, 1H), 2.98 (t, <i>J</i> = 6.3 Hz, 2H), 2.09 (dd, <i>J</i> = 15.8, 10.8 Hz, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.29, 156.84, 156.59, 155.96, 150.94, 150.01, 131.13 (2C), 130.27, 129.93 (2C), 129.29, 128.63, 127.50, 123.84, 119.44 (2C), 118.74 (2C), 110.38, 101.98, 45.95, 43.84, 26.23, 19.34. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 426.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>, 426.1925; found, 426.1926. [α]<sup>20</sup><sub>D</sub> +87.0 (<i>c</i> 0.05, MeOH).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-<i>N</i>-(4-Amino-5-(4-phenoxyphenyl)-6,7,8,9-tetrahydropyrimido[5,4-<i>b</i>]indolizin-8-yl)acrylamide (<b>5S</b>)</h4><div class="NLM_p last">White solid. Yield 246 mg, 57.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.13 (s, 1H), 7.50 (d, <i>J</i> = 7.2 Hz, 1H), 7.39–7.27 (m, 4H), 7.12 (t, <i>J</i> = 7.3 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 4H), 6.36–6.07 (m, 2H), 5.64 (d, <i>J</i> = 11.5 Hz, 1H), 4.57–4.45 (m, 1H), 4.40 (dd, <i>J</i> = 12.5, 5.2 Hz, 1H), 3.85 (dd, <i>J</i> = 12.4, 8.4 Hz, 1H), 2.97–2.90 (m, 2H), 2.26–2.10 (m, 1H), 1.93–1.75 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 165.96, 156.89, 156.51, 155.98, 150.04, 149.04, 131.10 (2C), 130.34, 130.04, 129.89 (2C), 128.31, 127.01, 123.83, 119.39 (2C), 118.71 (2C), 110.37, 101.88, 45.40, 44.17, 26.60, 20.05. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 426.2. HRMS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>, 426.1925; found, 426.1930. [α]<sup>20</sup><sub>D</sub> −76.0 (<i>c</i> 0.05, MeOH).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(4-Amino-5-(4-phenoxyphenyl)-6,7,8,9-tetrahydropyrimido[5,4-<i>b</i>]indolizin-8-yl)propionamide (<b>6</b>)</h4><div class="NLM_p">To a solution of intermediate <b>32</b> in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) was added propanoic acid (81 mg, 1.1 mmol), HATU (418 mg, 1.1 mmol), and Et<sub>3</sub>N (0.28 mL, 2.0 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 1.5 h and quenched with water (10 mL). After extraction with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL), the combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>6</b> (312 mg, 73.0%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 7.44–7.30 (m, 4H), 7.16 (t, J = 7.4 Hz, 1H), 7.09 (d, J = 8.5 Hz, 4H), 5.97 (d, J = 7.5 Hz, 1H), 5.09 (s, 2H), 4.71–4.53 (m, 1H), 4.44 (dd, J = 12.7, 4.7 Hz, 1H), 4.00 (dd, J = 12.7, 6.7 Hz, 1H), 2.97 (t, J = 6.3 Hz, 2H), 2.26 (q, J = 15.2, 7.6 Hz, 2H), 2.14–1.92 (m, 2H), 1.18 (t, J = 7.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 173.66, 156.87, 156.57, 155.79, 150.45, 149.81, 131.12 (2C), 129.93 (2C), 129.51, 128.56, 123.85, 119.45 (2C), 118.75 (2C), 110.38, 101.91, 46.03, 43.65, 29.70, 26.38, 19.53, 9.87. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 428.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>, 428.2081; found, 428.2075.</div><div class="NLM_p last">Compounds <b>7R</b> and <b>7S</b> were prepared following the synthetic procedure for racemate <b>7</b> from their corresponding enantiomeric precursors.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>7</b>)</h4><div class="NLM_p last">To a solution of intermediate <b>14</b> in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added acrylic anhydride (115 μL, 1.0 mmol) and Et<sub>3</sub>N (154 μL, 1.1 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. After completion, the mixture was added water (5 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The organic phase was separated and washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>7</b> (191 mg, 45.1%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.08 (s, 1H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H), 7.35–7.29 (m, 2H), 7.14–7.06 (m, 1H), 7.05–6.99 (m, 4H), 6.32–6.07 (m, 2H), 5.67–5.58 (m, 2H), 5.42 (d, <i>J</i> = 2.5 Hz, 1H), 5.10 (d, <i>J</i> = 2.1 Hz, 1H), 4.56 (dd, <i>J</i> = 11.4, 8.3 Hz, 1H), 3.87 (dd, <i>J</i> = 11.4, 5.7 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 165.74, 157.06, 156.46, 155.68, 150.38, 145.43, 137.59, 133.07, 130.61 (2C), 129.48, 129.38 (2C), 126.90, 126.68, 123.49, 119.02 (2C), 118.15 (2C), 108.34, 108.21, 105.37, 54.08, 47.55. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 424.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 424.1768; found, 424.1765.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>7R</b>)</h4><div class="NLM_p last">White solid. Yield 203 mg, 48.0%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.45 (d, <i>J</i> = 8.7 Hz, 2H), 7.43–7.36 (m, 2H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 4H), 6.44–6.10 (m, 3H), 5.80–5.64 (m, 2H), 5.51 (d, <i>J</i> = 2.1 Hz, 1H), 5.18 (d, <i>J</i> = 1.9 Hz, 1H), 5.04 (s, 2H), 4.67 (dd, <i>J</i> = 11.5, 8.1 Hz, 1H), 3.98 (dd, <i>J</i> = 11.6, 4.8 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.99, 157.52, 157.10, 156.21, 151.22, 146.02, 138.25, 133.36, 131.14 (2C), 130.07, 129.93 (2C), 127.53, 127.28, 124.02, 119.57 (2C), 118.66 (2C), 108.80, 108.72, 105.85, 54.62, 48.26. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 424.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 424.1768; found, 424.1762. [α]<sup>20</sup><sub>D</sub> +107.3 (c 0.05, MeOH).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>7S</b>)</h4><div class="NLM_p last">White solid. Yield 184 mg, 43.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.23 (s, 1H), 7.50–7.35 (m, 4H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.3 Hz, 4H), 6.45–6.11 (m, 3H), 5.74 (d, <i>J</i> = 10.2 Hz, 1H), 5.72–5.64 (m, 1H), 5.51 (d, <i>J</i> = 2.0 Hz, 1H), 5.18 (d, <i>J</i> = 1.7 Hz, 1H), 5.10 (s, 2H), 4.66 (dd, <i>J</i> = 11.6, 8.0 Hz, 1H), 3.98 (dd, <i>J</i> = 11.6, 4.8 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.34, 157.54, 157.11, 156.30, 152.21, 146.89, 138.54, 132.95, 131.21 (2C), 130.02, 129.99 (2C), 127.92, 127.59, 124.07, 119.64 (2C), 118.71 (2C), 108.84, 108.69, 106.20, 55.11, 49.10. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 424.4. HRMS (ESI) calcd for C<sub>25</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 424.1768; found, 424.1771. [α]<sup>20</sup><sub>D</sub> −106.0 (c 0.05, MeOH).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure for Synthesis of Compound <b>8–13</b>, <b>15</b></h3><div class="NLM_p">To a solution of intermediate <b>14</b> in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) was added corresponding R<sup>4</sup>-COOH (1.1 mmol), HATU (418 mg, 1.1 mmol), and Et<sub>3</sub>N (0.28 mL, 2.0 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 1.5 h. After completion, the mixture was diluted with water (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compounds <b>8</b>–<b>13</b> and <b>15</b>.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(2-((4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)amino)-2-oxoethyl)acrylamide (<b>8</b>)</h4><div class="NLM_p last">White solid. Yield 418 mg, 87.0%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.08 (s, 1H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H), 7.32 (dd, <i>J</i> = 8.4, 7.6 Hz, 2H), 7.10 (t, <i>J</i> = 7.4 Hz, 1H), 7.06–6.98 (m, 4H), 6.26–6.07 (m, 2H), 5.62 (dd, <i>J</i> = 9.5, 2.2 Hz, 1H), 5.54–5.45 (m, 1H), 5.41 (d, <i>J</i> = 2.4 Hz, 1H), 5.08 (d, <i>J</i> = 2.1 Hz, 1H), 4.54 (dd, <i>J</i> = 11.4, 8.4 Hz, 1H), 3.91 (s, 2H), 3.84 (dd, <i>J</i> = 11.4, 5.7 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 169.02, 166.21, 157.06, 156.53, 155.70, 150.55, 145.48, 137.22, 132.86, 130.61 (2C), 129.39 (2C), 129.35, 126.79, 126.70, 123.49, 119.03 (2C), 118.15 (2C), 109.50, 108.36, 108.16, 105.39, 54.15, 47.54, 42.26. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 481.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>N<sub>6</sub>O<sub>3</sub>, 481.1983; found, 481.1983.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-((2<i>S</i>)-1-((4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)amino)-1-oxopropan-2-yl)acrylamide (<b>9</b>)</h4><div class="NLM_p last">White solid. Yield 392 mg, 79.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.11 (s, 0.5H), 8.10 (s, 0.5H), 7.41–7.30 (m, 4H), 7.11 (t, <i>J</i> = 7.4 Hz, 1H), 7.04 (dd, <i>J</i> = 8.4, 1.7 Hz, 4H), 6.27–6.05 (m, 2H), 5.65–5.59 (m, 1H), 5.53–5.45 (m, 1H), 5.42 (s, 1H), 5.06 (s, 1H), 4.57 (ddd, <i>J</i> = 11.5, 8.4, 2.9 Hz, 1H), 4.51–4.40 (m, 1H), 3.85 (dt, <i>J</i> = 11.5, 5.6 Hz, 1H), 1.34 (dd, <i>J</i> = 6.9, 5.0 Hz, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 173.07 (0.5C), 172.96 (0.5C), 166.00 (0.5C), 165.94 (0.5C), 157.58, 156.97, 156.21, 151.01, 146.02, 137.63, 133.44 (0.5C), 133.40 (0.5C), 131.15 (2C), 130.01, 129.94 (2C), 127.39 (0.5C), 127.34 (0.5C), 127.22, 124.04, 119.58 (2C), 118.68 (2C), 108.90 (0.5C), 108.84 (0.5C), 108.76 (0.5C), 108.52 (0.5C), 105.90, 54.65 (0.5C), 54.54 (0.5C), 48.60, 48.07, 18.01 (0.5C), 17.73 (0.5C). MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 495.3. HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>, 495.2139; found, 495.2145.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-Acrylamido-<i>N</i>-(4-amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)cyclopropanecarboxamide (<b>10</b>)</h4><div class="NLM_p last">White solid. Yield 332 mg, 65.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.08 (s, 1H), 7.41–7.32 (m, 4H), 7.12 (t, <i>J</i> = 7.4 Hz, 1H), 7.04 (d, <i>J</i> = 8.5 Hz, 4H), 6.28–5.99 (m, 2H), 5.60 (dd, <i>J</i> = 10.2, 1.4 Hz, 1H), 5.57–5.50 (m, 1H), 5.42 (d, <i>J</i> = 2.5 Hz, 1H), 5.13 (d, <i>J</i> = 2.1 Hz, 1H), 4.58 (dd, <i>J</i> = 11.3, 8.6 Hz, 1H), 3.83 (dd, <i>J</i> = 11.4, 6.1 Hz, 1H), 1.65–1.45 (m, 2H), 1.09–0.96 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 172.30, 167.51, 157.51, 157.10, 156.26, 151.24, 146.01, 138.10, 133.42, 131.17 (2C), 129.93 (2C), 127.69, 127.34, 123.99, 119.55 (2C), 118.69 (2C), 108.67, 108.51, 105.91, 77.29, 54.80, 48.16, 34.94, 17.08, 16.91. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 507.3. HRMS (ESI) calcd for C<sub>29</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>, 507.2139; found, 507.2147.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(3-((4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)amino)-3-oxopropyl)acrylamide (<b>11</b>)</h4><div class="NLM_p last">White solid. Yield 448 mg, 90.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.09 (s, 1H), 7.37 (d, <i>J</i> = 8.6 Hz, 2H), 7.35–7.29 (m, 2H), 7.10 (t, <i>J</i> = 7.4 Hz, 1H), 7.02 (d, <i>J</i> = 8.6 Hz, 4H), 6.21–5.98 (m, 2H), 5.55 (dd, <i>J</i> = 9.9, 1.9 Hz, 1H), 5.52–5.43 (m, 1H), 5.40 (d, <i>J</i> = 2.3 Hz, 1H), 5.04 (d, <i>J</i> = 2.0 Hz, 1H), 4.53 (dd, <i>J</i> = 11.3, 8.2 Hz, 1H), 3.81 (dd, <i>J</i> = 11.4, 5.7 Hz, 1H), 2.43 (t, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 172.26, 166.81, 157.53, 157.16, 156.18, 151.23, 145.98, 137.86, 133.39, 131.13 (2C), 130.35, 129.92 (2C), 127.27, 126.69, 124.02, 119.56 (2C), 118.64 (2C), 108.79, 108.49, 105.93, 54.67, 48.18, 35.80, 35.30. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 495.4. HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>, 495.2139; found, 495.2140.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)-4-(dimethylamino)but-2-enamide (<b>12</b>)</h4><div class="NLM_p">White solid. Yield 333 mg, 69.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.47 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (t, <i>J</i> = 7.9 Hz, 2H), 7.20–7.15 (m, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 4H), 6.92 (dt, <i>J</i> = 15.0, 6.0 Hz, 1H), 6.14–6.00 (m, 2H), 5.76–5.61 (m, 1H), 5.51 (d, <i>J</i> = 1.9 Hz, 1H), 5.17 (d, <i>J</i> = 1.7 Hz, 1H), 5.04 (s, 2H), 4.69 (dd, <i>J</i> = 11.7, 7.9 Hz, 1H), 3.97 (dd, <i>J</i> = 11.6, 4.8 Hz, 1H), 3.12 (dd, <i>J</i> = 5.7, 0.7 Hz, 2H), 2.30 (s, 6H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 165.31, 157.52, 157.19, 156.32, 152.36, 146.93, 142.25, 138.65, 132.93, 131.24 (2C), 130.00 (2C), 127.68, 124.79, 124.06, 119.65 (2C), 118.72 (2C), 108.79, 108.53, 106.24, 60.25, 55.07, 49.05, 45.48. <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 165.31, 157.52, 157.19, 156.32, 152.36, 146.93, 142.25, 138.65, 132.93, 131.24 (2C), 130.00 (2C), 127.68, 124.79, 124.06, 119.65 (2C), 118.72 (2C), 108.79, 108.53, 106.24, 60.25, 55.07, 49.05, 45.48. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 481.3. HRMS (ESI) calcd for C<sub>28</sub>H<sub>29</sub>N<sub>6</sub>O<sub>2</sub>, 481.2347; found, 481.2334.</div><div class="NLM_p last">Compounds <b>13R</b> and <b>13S</b> were prepared following the synthetic procedure for racemate <b>13</b> from their corresponding enantiomeric precursors.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)but-2-ynamide (<b>13</b>)</h4><div class="NLM_p last">White solid. Yield 381 mg, 87.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.46 (d, <i>J</i> = 8.6 Hz, 2H), 7.40 (t, <i>J</i> = 8.0 Hz, 2H), 7.18 (t, <i>J</i> = 7.4 Hz, 1H), 7.14–7.07 (m, 4H), 6.30 (d, <i>J</i> = 8.4 Hz, 1H), 5.68–5.57 (m, 1H), 5.53 (d, <i>J</i> = 2.0 Hz, 1H), 5.21 (d, <i>J</i> = 1.4 Hz, 1H), 5.16 (s, 2H), 4.67 (dd, <i>J</i> = 11.7, 7.9 Hz, 1H), 3.98 (dd, <i>J</i> = 11.7, 5.0 Hz, 1H), 1.97 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.60, 157.02, 156.29, 153.25, 152.02, 146.85, 137.94, 132.79, 131.20 (2C), 130.00 (2C), 127.50, 124.08, 119.66 (2C), 118.74 (2C), 108.99, 108.93, 106.19, 85.12, 74.32, 55.18, 48.82, 3.74. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 436.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 436.1768; found, 436.1757.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-<i>N</i>-(4-amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)but-2-ynamide (<b>13R</b>)</h4><div class="NLM_p last">White solid. Yield 390 mg, 89.6%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.22 (s, 1H), 7.47–7.36 (m, 4H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 4H), 6.44 (d, <i>J</i> = 8.2 Hz, 1H), 5.69–5.57 (m, 1H), 5.52 (s, 1H), 5.20 (s, 3H), 4.65 (dd, <i>J</i> = 11.6, 8.0 Hz, 1H), 3.97 (dd, <i>J</i> = 11.5, 4.9 Hz, 1H), 1.95 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.54, 157.25, 156.32, 153.26, 152.34, 146.92, 137.99, 132.69, 131.20 (2C), 129.98 (2C), 127.59, 124.05, 119.63 (2C), 118.72 (2C), 108.92, 108.77, 106.23, 85.07, 74.33, 55.19, 48.78, 3.71. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 436.4. HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 436.1768; found, 436.1767. [α]<sup>20</sup><sub>D</sub> +134.0 (c 0.05, MeOH).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)but-2-ynamide (<b>13S</b>)</h4><div class="NLM_p last">White solid. Yield 365 mg, 83.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 7.43–7.36 (m, 2H), 7.21–7.15 (m, 1H), 7.10 (d, <i>J</i> = 8.6 Hz, 4H), 6.33 (d, <i>J</i> = 8.1 Hz, 1H), 5.69–5.57 (m, 1H), 5.52 (d, <i>J</i> = 2.1 Hz, 1H), 5.20 (d, <i>J</i> = 1.6 Hz, 1H), 5.09 (s, 2H), 4.66 (dd, <i>J</i> = 11.6, 8.0 Hz, 1H), 3.97 (dd, <i>J</i> = 11.6, 4.9 Hz, 1H), 1.96 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.55, 157.23, 156.31, 153.26, 152.57, 152.45, 146.98, 137.98, 132.66, 131.21 (2C), 129.99 (2C), 127.61, 124.06, 119.64 (2C), 118.72 (2C), 108.91, 108.77, 106.26, 85.10, 74.31, 55.20, 48.80, 3.74. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 436.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>, 436.1768; found, 436.1780. [α]<sup>20</sup><sub>D</sub> −150.0 (c 0.05, MeOH).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-Methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizine-4,7-diamine (<b>14</b>)</h4><div class="NLM_p last">To a solution of intermediate <b>33</b> (470 mg, 1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added trifluoroacetic acid (1.9 mL) dropwise. The mixture was stirred at room temperature for 3 h. After completion, the mixture was added saturated NaHCO<sub>3</sub> solution dropwise until neutral and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product <b>14</b> (362 mg, 98.0%) was given as yellowish solid and could be used in next step without further purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.23 (s, 1H), 7.47 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (t, <i>J</i> = 7.9 Hz, 2H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.5 Hz, 4H), 5.49 (d, <i>J</i> = 1.6 Hz, 1H), 5.43 (s, 2H), 5.19 (s, 1H), 4.68–4.50 (m, 2H), 3.81 (dd, <i>J</i> = 9.7, 4.4 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 153.36, 153.23, 152.51, 148.20, 143.00, 139.19, 129.83, 127.35 (2C), 126.01 (2C), 124.19, 120.00, 115.61 (2C), 114.78 (2C), 104.37, 103.01, 102.11, 54.42, 46.98. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 370.3. HRMS (ESI) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O, 370.1662; found, 370.1652.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)propionamide (<b>15</b>)</h4><div class="NLM_p">White solid. Yield 314 mg, 73.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.06 (s, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 2H), 7.31 (t, <i>J</i> = 7.9 Hz, 2H), 7.08 (t, <i>J</i> = 7.5 Hz, 1H), 7.01 (d, <i>J</i> = 8.3 Hz, 4H), 5.57–5.48 (m, 1H), 5.39 (s, 1H), 5.05 (s, 1H), 4.51 (dd, <i>J</i> = 11.4, 8.4 Hz, 1H), 3.80 (dd, <i>J</i> = 11.4, 5.8 Hz, 1H), 2.19 (q, <i>J</i> = 7.7 Hz, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 179.00, 161.49, 161.17, 160.18, 155.28, 149.97, 142.34, 137.44, 135.10 (2C), 133.85 (2C), 131.27, 127.95, 123.48 (2C), 122.61 (2C), 112.69, 112.33, 109.91, 58.55, 58.43, 52.15, 52.11, 33.21, 33.16, 13.60. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 426.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>, 426.1925; found, 426.1926.</div><div class="NLM_p last">Compounds <b>16</b>–<b>19</b> were prepared following the synthetic procedure of compound <b>7</b> staring from intermediates <b>36a</b>–<b>d</b>.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>S</i>)-<i>N</i>-(4-Amino-5-(4-(4-(<i>tert</i>-butyl)phenoxy)phenyl)-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>16</b>)</h4><div class="NLM_p last">White solid. Yield 354 mg, 73.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 7.40 (dd, <i>J</i> = 8.7, 3.0 Hz, 4H), 7.05 (dd, <i>J</i> = 16.2, 8.6 Hz, 4H), 6.62 (d, <i>J</i> = 8.1 Hz, 1H), 6.46–6.12 (m, 2H), 5.73 (d, <i>J</i> = 10.3 Hz, 2H), 5.54–5.45 (m, 1H), 5.17 (s, 1H), 5.15 (s, 2H), 4.63 (dd, <i>J</i> = 11.5, 8.0 Hz, 1H), 3.97 (dd, <i>J</i> = 11.5, 4.6 Hz, 1H), 1.34 (s, 9H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.37, 157.90, 157.08, 153.73, 152.05, 147.06, 146.78, 138.53, 132.99, 131.12 (2C), 130.09, 127.82, 127.19, 126.79 (2C), 119.22 (2C), 118.42 (2C), 108.93, 108.73, 106.16, 55.10, 49.09, 34.42, 31.50 (3C). MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 480.4. HRMS (ESI) calcd for C<sub>29</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub>, 480.2394; found, 480.2403. [α]<sup>20</sup><sub>D</sub> −92.0 (c 0.05, MeOH).</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>S</i>)-<i>N</i>-(4-Amino-5-(4-(4-fluorophenoxy)phenyl)-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>17</b>)</h4><div class="NLM_p last">White solid. Yield 286 mg, 64.8%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.11–7.00 (m, 6H), 6.48 (d, <i>J</i> = 7.9 Hz, 1H), 6.44–6.12 (m, 2H), 5.78–5.64 (m, 2H), 5.51 (s, 1H), 5.23 (s, 2H), 5.19 (s, 1H), 4.66 (dd, <i>J</i> = 11.5, 8.0 Hz, 1H), 3.99 (dd, <i>J</i> = 11.8, 4.8 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.36, 160.25, 158.32, 157.95, 156.82, 151.90, 151.59, 146.71, 138.49, 133.17, 131.23 (2C), 130.03, 127.90, 127.41, 121.37, 121.31, 118.15 (2C), 116.70, 116.51, 108.85, 106.06, 55.08, 49.09. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 442.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>2</sub>, 442.1674; found, 442.1681. [α]<sup>20</sup><sub>D</sub> −109.3 (c 0.05, MeOH).</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>S</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-(4-(trifluoromethyl)phenoxy)phenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>18</b>)</h4><div class="NLM_p last">White solid. Yield 377 mg, 76.7%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.18 (s, 1H), 7.63 (d, <i>J</i> = 8.5 Hz, 2H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.14 (d, <i>J</i> = 8.2 Hz, 4H), 6.68 (d, <i>J</i> = 8.5 Hz, 1H), 6.45–6.11 (m, 2H), 5.79–5.65 (m, 2H), 5.50 (d, <i>J</i> = 1.5 Hz, 1H), 5.33 (s, 2H), 5.20 (d, <i>J</i> = 0.9 Hz, 1H), 4.64 (dd, <i>J</i> = 11.5, 8.0 Hz, 1H), 3.98 (dd, <i>J</i> = 11.6, 4.8 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.43, 159.57, 157.05, 156.00, 151.87, 146.70, 138.51, 133.20, 131.51 (2C), 130.03, 128.92, 127.91, 127.37, 127.35, 126.12, 125.87, 125.60, 125.34, 125.15, 122.99, 119.84 (2C), 118.70 (2C), 108.87, 108.57, 106.01, 55.06, 50.74, 49.02. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 492.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 492.1642; found, 492.1649. [α]<sup>20</sup><sub>D</sub> −86.0 (c 0.05, MeOH).</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-<i>N</i>-(4-Amino-6-methylene-5-(4-(4-(trifluoromethoxy)phenoxy)phenyl)-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)acrylamide (<b>19</b>)</h4><div class="NLM_p last">White solid. Yield 345 mg, 68.0%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.21 (s, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 2H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 7.10 (d, <i>J</i> = 7.6 Hz, 4H), 6.47 (d, <i>J</i> = 8.2 Hz, 1H), 6.44–6.10 (m, 2H), 5.79–5.65 (m, 2H), 5.51 (d, <i>J</i> = 1.8 Hz, 1H), 5.27 (s, 2H), 5.19 (d, <i>J</i> = 0.9 Hz, 1H), 4.66 (dd, <i>J</i> = 11.6, 8.0 Hz, 1H), 3.99 (dd, <i>J</i> = 11.6, 4.9 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.36, 157.05, 156.94, 154.86, 151.76, 146.77, 145.09, 138.52, 133.16, 131.37 (2C), 130.01, 128.15, 127.93, 122.80 (2C), 120.43 (2C), 118.94 (2C), 108.83, 108.72, 106.06, 55.09, 49.09. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 508.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>, 508.1591; found, 508.1605. [α]<sup>20</sup><sub>D</sub> −82.0 (c 0.05, MeOH).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> General Procedure for Synthesis of Compound <b>20</b>–<b>24</b></h3><div class="NLM_p">To a solution of compound <b>37e</b>–<b>i</b> (1.0 mmol) in THF (15 mL) was added PdCl<sub>2</sub>dppf (76 mg, 0.1 mmol). 4 N NaOH aqueous solution (3 mL, 12.0 mmol) was added, and the mixture was stirred at 85 oC for 15 h under N<sub>2</sub>. After completion, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>38e</b>–<b>i</b> as yellowish solid. Compounds <b>20</b>–<b>24</b> were prepared following the synthetic procedure of compound <b>7</b> staring from intermediates <b>38e</b>–<b>i</b>.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>S</i>)-4-(7-Acrylamido-4-amino-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-5-yl)-<i>N</i>-(pyridin-2-yl)benzamide (<b>20</b>)</h4><div class="NLM_p last">White solid. Yield 248 mg, 55.0%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.89 (s, 1H), 8.39 (d, <i>J</i> = 8.4 Hz, 1H), 8.31 (d, <i>J</i> = 5.0 Hz, 1H), 8.21 (s, 1H), 8.02 (d, <i>J</i> = 8.0 Hz, 2H), 7.78 (t, <i>J</i> = 7.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.1 Hz, 2H), 7.16–7.05 (m, 1H), 6.50 (d, <i>J</i> = 7.6 Hz, 1H), 6.45–6.11 (m, 2H), 5.82–5.66 (m, 2H), 5.49 (s, 1H), 5.18 (s, 3H), 4.68 (dd, <i>J</i> = 11.6, 8.1 Hz, 1H), 3.99 (dd, <i>J</i> = 11.6, 4.9 Hz, 1H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 220.96, 165.44, 165.25, 157.18, 152.60, 151.44, 148.00, 147.24, 138.64, 138.42, 137.71, 133.64, 133.32, 130.26 (2C), 129.98, 128.09, 128.06 (2C), 120.23, 114.31, 109.19, 108.22, 105.79, 55.01, 49.03. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 452.2. HRMS (ESI) calcd for C<sub>25</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>, 452.1829; found, 452.1838. [α]<sup>20</sup><sub>D</sub> −97.3 (c 0.05, MeOH).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>S</i>)-4-(7-Acrylamido-4-amino-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-5-yl)-<i>N</i>-(4-(trifluoromethyl)pyridin-2-yl)benzamide (<b>21</b>)</h4><div class="NLM_p last">White solid. Yield 276 mg, 61.1%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 8.44 (d, <i>J</i> = 5.1 Hz, 1H), 8.13 (s, 1H), 8.05 (d, <i>J</i> = 8.3 Hz, 2H), 7.70 (d, <i>J</i> = 8.2 Hz, 1H), 7.63 (d, <i>J</i> = 8.3 Hz, 2H), 7.28 (d, <i>J</i> = 4.7 Hz, 1H), 6.36–6.10 (m, 2H), 5.67 (d, <i>J</i> = 8.7 Hz, 2H), 5.46 (d, <i>J</i> = 2.0 Hz, 1H), 5.16 (d, <i>J</i> = 1.4 Hz, 1H), 4.60 (dd, <i>J</i> = 11.4, 8.5 Hz, 1H), 3.93 (dd, <i>J</i> = 11.5, 5.6 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 166.11, 165.65, 156.86, 152.52, 151.28, 148.92, 146.46, 141.15, 140.88, 140.61, 140.34, 138.11, 137.74, 133.94, 132.94, 130.21 (2C), 129.96, 128.28 (2C), 127.61, 125.87, 123.69, 121.52, 119.35, 115.64, 115.61, 110.56, 110.53, 109.26, 108.23, 105.47, 54.62, 48.19. MS (ESI, [M - H]<sup>−</sup>) <i>m</i>/<i>z</i> 518.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>19</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>, 518.1558; found, 518.1567. [α]<sup>20</sup><sub>D</sub> −84.0 (c 0.05, MeOH).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-((<i>S</i>)-7-Acrylamido-4-amino-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-5-yl)-<i>N</i>-((<i>S</i>)-1-(pyridin-2-yl)ethyl)benzamide (<b>22</b>)</h4><div class="NLM_p last">White solid. Yield 304 mg, 63.4%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.58 (d, <i>J</i> = 4.7 Hz, 1H), 8.20 (s, 1H), 8.01 (d, <i>J</i> = 7.1 Hz, 1H), 7.96 (d, <i>J</i> = 8.1 Hz, 2H), 7.71 (t, <i>J</i> = 7.7 Hz, 1H), 7.55 (d, <i>J</i> = 7.9 Hz, 2H), 7.32 (d, <i>J</i> = 7.9 Hz, 1H), 7.23 (d, <i>J</i> = 7.4 Hz, 1H), 6.58 (d, <i>J</i> = 7.2 Hz, 1H), 6.45–6.14 (m, 2H), 5.80–5.68 (m, 2H), 5.49 (s, 1H), 5.44–5.28 (m, 3H), 5.18 (s, 1H), 4.68 (dd, <i>J</i> = 11.5, 8.2 Hz, 1H), 4.02 (dd, <i>J</i> = 11.9, 5.0 Hz, 1H), 1.60 (d, <i>J</i> = 6.7 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 165.92, 165.44, 160.72, 156.52, 151.16, 149.01, 146.83, 138.31, 137.09, 136.38, 134.28, 133.56, 130.03, 129.87 (2C), 127.99 (2C), 127.94, 122.56, 121.66, 109.41, 108.72, 105.65, 54.97, 50.20, 49.08, 22.98. MS (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 480.3. HRMS (ESI) calcd for C<sub>27</sub>H<sub>26</sub>N<sub>7</sub>O<sub>2</sub>, 480.2142; found, 480.2147. [α]<sup>20</sup><sub>D</sub> −41.3 (c 0.05, MeOH).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>S</i>)-4-(7-Acrylamido-4-amino-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-5-yl)-<i>N</i>-benzylbenzamide (<b>23</b>)</h4><div class="NLM_p last">White solid. Yield 358 mg, 79.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.03 (s, 1H), 7.82 (d, <i>J</i> = 8.3 Hz, 2H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 7.27–7.21 (m, 4H), 7.21–7.15 (m, 1H), 6.29–6.05 (m, 2H), 5.60 (dd, <i>J</i> = 10.0, 1.7 Hz, 1H), 5.58–5.52 (m, 1H), 5.34 (d, <i>J</i> = 2.3 Hz, 1H), 5.04 (d, <i>J</i> = 1.9 Hz, 1H), 4.53 (s, 2H), 4.52–4.45 (m, 1H), 3.83 (dd, <i>J</i> = 11.4, 5.7 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 167.43, 167.36, 166.17, 157.06, 151.49, 146.33, 138.10, 136.59, 133.63, 130.00, 129.85 (2C), 128.65 (2C), 127.92 (2C), 127.73 (2C), 127.49 (2C), 108.95, 108.34, 105.52, 54.56, 48.07, 44.06, 43.93. (ESI, [M + H]<sup>+</sup>) <i>m</i>/<i>z</i> 465.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub>, 465.2034; found, 465.2041. [α]<sup>20</sup><sub>D</sub> −82.0 (c 0.05, MeOH).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-((<i>S</i>)-7-Acrylamido-4-amino-6-methylene-7,8-dihydro-6<i>H</i>-pyrimido[5,4-<i>b</i>]pyrrolizin-5-yl)-<i>N</i>-((<i>R</i>)-2-methoxy-1-phenylethyl)benzamide (<b>24</b>)</h4><div class="NLM_p last">White solid. Yield 202 mg, 44.7%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.15 (s, 1H), 7.87 (d, <i>J</i> = 8.2 Hz, 2H), 7.52 (d, <i>J</i> = 8.2 Hz, 2H), 7.37–7.22 (m, 6H), 6.36–6.03 (m, 2H), 5.70–5.60 (m, 2H), 5.42 (d, <i>J</i> = 2.3 Hz, 1H), 5.31 (t, <i>J</i> = 5.0 Hz, 1H), 5.11 (d, <i>J</i> = 1.8 Hz, 1H), 4.60 (dd, <i>J</i> = 11.5, 8.1 Hz, 1H), 3.90 (dd, <i>J</i> = 11.6, 5.5 Hz, 1H), 3.73 (d, <i>J</i> = 4.8 Hz, 2H), 3.34 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 166.52, 165.68, 157.09, 152.09, 146.82, 139.59, 138.30, 136.90, 133.71, 133.44, 130.00 (2C), 129.95, 128.64 (2C), 127.96 (2C), 127.80, 127.66, 126.78 (2C), 109.08, 108.38, 105.78, 74.90, 59.13, 54.75, 53.05, 48.59. MS (ESI, [M - H]<sup>−</sup>) <i>m</i>/<i>z</i> 507.4. HRMS (ESI) calcd for C<sub>29</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>, 507.2150; found, 507.2159. [α]<sup>20</sup><sub>D</sub> −43.7 (c 0.05, MeOH).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-((<i>tert</i>-Butoxycarbonyl)amino)but-3-en-1-yl methanesulfonate (<b>26</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (1.87 g, 10.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added methanesulfonyl chloride (0.85 mL, 11.0 mmol) and triethylamine (1.7 mL, 12.0 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature slowly for 3 h. After completion of the reaction, water (20 mL) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added. The organic phase was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (petroleum ether/EtOAc) to give compound <b>26</b> (2.27 g, 85.4%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.78 (ddd, <i>J</i> = 15.8, 10.2, 5.2 Hz, 1H), 5.39–5.15 (m, 2H), 4.91 (d, <i>J</i> = 6.9 Hz, 1H), 4.43 (s, 1H), 4.32–4.12 (m, 2H), 3.00 (s, 3H), 1.42 (s, 9H).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl (1-(4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)but-3-en-2-yl) carbamate (<b>27</b>)</h4><div class="NLM_p last">To a solution of 4-chloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (279 mg, 1.0 mmol) in dry DMF (7 mL) was added K<sub>2</sub>CO<sub>3</sub> (276 mg, 2.0 mmol) and compound <b>26</b> (398 mg, 1.5 mmol). The mixture was stirred at 55 °C for 12 h under N<sub>2</sub>. After completion of the reaction, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic phase was washed with water (3 mL) and brine (3 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>27</b> (332 mg, 74.1%) as pale yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 7.39 (s, 1H), 5.82 (ddd, <i>J</i> = 17.1, 10.5, 5.5 Hz, 1H), 5.33–5.14 (m, 2H), 4.80 (s, 1H), 4.63–4.51 (m, 1H), 4.51–4.42 (m, 1H), 4.35 (s, 1H), 1.33 (s, 9H).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (1-(4-amino-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)but-3-en-2-yl) carbamate (<b>28</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (449 mg, 1.0 mmol) in 1,4-dioxane (10 mL) in a seal tube was added ammonia (10 mL, 25% ∼28%). The mixture was stirred at 120 oC for 3 h under pressure. After completion of the reaction, the mixture was cooled to room temperature and was diluted with water (5 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (petroleum ether/EtOAc) to give compound <b>28</b> (324 mg, 75.4%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.05 (s, 1H), 5.87–5.74 (m, 1H), 5.72 (s, 2H), 5.34–5.13 (m, 3H), 4.56–4.43 (m, 1H), 4.34 (dd, <i>J</i> = 14.8, 4.9 Hz, 1H), 4.30–4.15 (m, 1H), 1.35 (s, 9H).</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>tert</i>-Butyl (1-(4-amino-5-(4-phenoxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl) but-3-en-2-yl)carbamate (<b>29</b>)</h4><div class="NLM_p last">To a solution of compound <b>28</b> (429 mg, 1.0 mmol) in 1,4-dioxane (5 mL) was added (4-phenoxyphenyl)boronic acid (321 mg, 1.5 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (231 mg, 0.2 mmol). 2 N Na<sub>2</sub>CO<sub>3</sub> aqueous solution (1 mL, 2.0 mmol) was added. The mixture was stirred at 90 °C overnight under N<sub>2</sub>. The mixture was cooled to room temperature and diluted with water (5 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic phase was washed with brine (3 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>29</b> (336 mg, 71.2%) as white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.32 (s, 1H), 7.45–7.34 (m, 4H), 7.15 (t, <i>J</i> = 7.5 Hz, 1H), 7.08 (dd, <i>J</i> = 8.4, 1.7 Hz, 4H), 6.95 (s, 1H), 5.84 (ddd, <i>J</i> = 16.7, 10.3, 5.4 Hz, 1H), 5.42 (s, 1H), 5.28 (d, <i>J</i> = 17.3 Hz, 1H), 5.20 (d, <i>J</i> = 10.6 Hz, 1H), 5.13 (s, 2H), 4.64–4.50 (m, 1H), 4.36 (s, 2H), 1.32 (s, 9H).</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl (1-(4-amino-6-bromo-5-(4-phenoxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-7-yl)but-3-en-2-yl)carbamate (<b>30</b>)</h4><div class="NLM_p last">To a solution of compound <b>29</b> (472 mg, 1.0 mmol) in DMF (10 mL) was added <i>N</i>-bromosuccinimide (196 mg, 1.1 mmol). The mixture was stirred at room temperature overnight in dark. After completion, the reaction was quenched with water (20 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic phase was washed with water (5 mL) and brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>30</b> (461 mg, 83.8%) as yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 7.39 (t, <i>J</i> = 8.2 Hz, 4H), 7.16 (t, <i>J</i> = 7.7 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 4H), 5.96–5.80 (m, 1H), 5.48 (d, <i>J</i> = 8.4 Hz, 1H), 5.38–5.15 (m, 4H), 4.66 (s, 1H), 4.52–4.37 (m, 1H), 4.36–4.22 (m, 1H), 1.24 (s, 9H).</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>tert</i>-Butyl (4-amino-5-(4-phenoxyphenyl)-6,7,8,9-tetrahydropyrimido[5,4-<i>b</i>] indolizin-8-yl)carbamate (<b>31</b>)</h4><div class="NLM_p last">To a solution of 9-BBN in dry THF (20 mL, 10.0 mmol) was added compound <b>30</b> (550 mg, 1.0 mmol) at 0 °C under N<sub>2</sub>. The mixture was allowed to warm to room temperature slowly for 5 h. After completion, the mixture was added 3N NaOH aqueous solution (4.7 mL, 14.0 mmol) and Pd(dppf)Cl<sub><b>2</b></sub> (190 mg, 0.25 mmol). The mixture was stirred at 85 °C for 15 h under N<sub>2</sub>, and then quenched with water (10 mL). After being extracted with ethyl acetate (3 × 10 mL), the combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (EtOAc) to give compound <b>31</b> (232 mg, 49.2%) as yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.42–7.31 (m, 4H), 7.15 (t, <i>J</i> = 7.5 Hz, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 4H), 5.05 (s, 2H), 4.86 (d, <i>J</i> = 8.0 Hz, 1H), 4.48 (dd, <i>J</i> = 12.6, 4.9 Hz, 1H), 4.27 (s, 1H), 3.94 (dd, <i>J</i> = 12.6, 7.1 Hz, 1H), 3.08–2.83 (m, 2H), 2.14–2.07 (m, 1H), 1.97–1.84 (m, 1H), 1.46 (s, 9H).</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>tert</i>-Butyl (4-amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6<i>H</i>- pyrimido[5,4-<i>b</i>]pyrrolizin-7-yl)carbamate (<b>33</b>)</h4><div class="NLM_p">To a solution of intermediate <b>30</b> (550 mg, 1.0 mmol) in THF (15 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (116 mg, 0.1 mmol). 4 N NaOH aqueous solution (3 mL, 12.0 mmol) was then added. The mixture was stirred at 85 °C for 15 h under N<sub>2</sub>. After being quenched with water (10 mL), the mixture was extracted with ethyl acetate (3 × 5 mL). The combined organic phase was washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CHCl<sub>3</sub>/MeOH) to give compound <b>33</b> (412 mg, 87.8%) as yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.22 (s, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 7.42–7.34 (m, 2H), 7.16 (t, <i>J</i> = 7.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 4H), 5.49 (s, 1H), 5.38–5.04 (m, 5H), 4.64 (dd, <i>J</i> = 11.3, 8.0 Hz, 1H), 3.93 (dd, <i>J</i> = 11.4, 5.4 Hz, 1H), 1.47 (s, 9H).</div><div class="NLM_p last">The procedures for synthesis of intermediates <b>36a</b>–<b>i</b> are similar to those for synthesis of intermediate <b>30S</b> by using <b>28S</b> and intermediates <b>35a</b>–<b>i</b>. The pinacol esters <b>35a</b>–<b>i</b> were prepared by following similar literature procedures.<a onclick="showRef(event, 'cit20f ref25'); return false;" href="javascript:void(0);" class="ref cit20f ref25">(20f,25)</a></div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Cell Culture</h3><div class="NLM_p last">Human lymphoma cell line Ramos was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). TMD8 cell was purchased from the Nanjing Cobioer Biological Technology (Nanjing, China). These cells were grown in RPMI-1640 (Gibco, USA) supplemented with FBS (Gibco, USA) at 37 °C in humidified 5% CO<sub>2</sub> incubator.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> In Vitro Enzymatic Activity Assay</h3><div class="NLM_p last">Kinase inhibitory activity of compound<b>s</b> were evaluated using the Enzyme-linked immunosorbent assay (ELISA). The kinase enzyme of BTK, BLK, ErbB4, EGFR, TEC, TXK, ITK, RET, ErbB2, Flt-3, BMX, PDGFR-β, EPH-A2, CSF1R was purchased from Eurofins (Brussels, Belgium), and BTK<sup>C481S</sup> was bought from SignalChem Lifesciences (British Columbia, Canada). A total of 20 μg/mL Poly(Glu, Tyr) 4:1 (Sigma, St Louis, MO) was precoated in 96-well ELISA plates as a substrate. Active kinases were incubated with indicated drugs in 1 × reaction buffer (50 mmol/L HEPES pH 7.4, 20 mmol/L MgCl<sub>2</sub>, 0.1 mmol/L MnCl<sub>2</sub>, 0.2 mmol/L Na<sub>3</sub>VO<sub>4</sub>, 1 mmol/L DTT) containing 5 μmol/L ATP at 37 °C for 1 h. After incubation, the wells were washed with PBS and then incubated with an antiphosphotyrosine (PY99) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by an incubation with horseradish peroxidase (HRP)-conjugated secondary antibody. The wells were visualized using <i>o</i>-phenylenediamine (OPD), and the absorbance was read with a multiwell spectrophotometer (VERSAmax, Molecular Devices, Sunnyvale, CA, USA) at 492 nm.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> MTT Assay</h3><div class="NLM_p last">The cell proliferation Ability was assessed by the thiazolyl blue tetrazolium bromide (MTT) assay. MTT analysis was subsequently performed as per the standard procedures. Briefly, the lymphoma cells were seeded in 96-well plates and grown for 2 h. The cells were then treated with various concentrations of PBS solution containing test compounds, with each concentration tested in triplicate, and then cells were cultured for an additional 72 h. The IC<sub>50</sub> values were obtained by using the Logit method and reported as the mean ± SD from three independent determinations.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Kinase Selectivity Profile</h3><div class="NLM_p last">The kinase selectivity profile was performed by using the DiscoveRx KINOMEscan platform (<a href="http://www.kinomescan.com/" class="extLink">http://www.kinomescan.com/</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The compound was screened at a concentration of 1 μM against a panel of 468 kinases. The results were defined as a percentage of signal between the negative (DMSO, 100% control) and the positive (control compound, 0% control) control, where the “% control” was calculated as follows: % control = [(test compound signal–positive control signal)/(negative control signal–positive control signal)] × 100.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Western Blot Analysis</h3><div class="NLM_p last">Western blot analysis was performed with standard procedures. Briefly, lymphoma cell lines were lysed in SDS lysis buffer and boiled for 30 min. Antibodies directed against the following proteins were used: BTK, <i>p</i>-BTK (Tyr223), PLCγ2, <i>p</i>-PLCγ2 (Tyr759), which were obtained from Cell Signaling Technologies (CST, Cambridge, MA, USA). β-Actin and α-tubulin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Washout Experiment</h3><div class="NLM_p last">TMD8 cells were seeded in six-well plates for 2 h and exposed to medium containing 1 μM of compound <b>7S</b> or ibrutinib. Subsequently, compound <b>7S</b> or ibrutinib was removed, and cells were washed by PBS three times. Then the normal medium was added, and protein samples were collected at different time points for Western Blot Analysis.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Flow Cytometric Analysis</h3><div class="NLM_p last">For the purpose of cell cycle arrest analysis, TMD8 cells were treated with compound <b>7S</b> and ibrutinib at the indicated concentrations for 48 h. Cell-cycle arrest was determined by the incorporation of propidium iodide (Sigma-Aldrich) into permeabilized cells. After incubating with drugs for 72 h, cells undergoing apoptosis were identified using an Annexin V-FITC kit (Vazyme Biotech), following the manufacturer’s instructions. Both cell cycle arrest and apoptosis were analyzed using a BD Aria III Flow Cytometer (BD Biosciences, San Jose, California, USA). Data were analyzed by Flow Jo software.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> In Vivo Antitumor Activity</h3><div class="NLM_p last">All experiments were performed in compliance with the Animal Ethics Procedures and Guidelines of the People’s Republic of China. The mice were maintained under the 12 h light/dark cycles condition in the specific pathogen free (SPF) cleanroom with fresh air (more than 50%), appropriate temperature (20–26 °C) and humidness (40–70%). All materials and containers were disinfected and sterilized before use. Four- to five-week-old female CB-17 SCID mice were inoculated subcutaneously into the right axilla with TMD8 DLBCL cells (approximately 2 × 10<sup>6</sup> cells/mouse). When the tumor size reached a volume of ∼100–200 mm<sup>3</sup>, animals were randomly assigned into control and treated groups (n = 6/group). For efficacy studies, mice in control and in treatment groups were treated with vehicle, compound <b>1</b> (25 mg/kg/day) and compound <b>7S</b> (5 mg/kg/day; 15 mg/kg/day) for continuous 13, 17, 13, and 17 days, respectively. Tumor burdens were measured by tumor volume. Once tumors reached 20 mm in diameter, mice were sacrificed by CO<sub>2</sub> asphyxiation. Protein level of <i>p</i>-BTK (Tyr223) and <i>p</i>-PLCγ2 (Tyr759) in tumor were determined using Western blot.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Immunohistochemical (IHC) Assays</h3><div class="NLM_p last">Fresh tumor tissues were fixed, embedded in paraffin, and sections (4 μM) were prepared. The immunohistochemical analysis was conducted by Wuhan Goodbio Technology Ltd., and the assay was operated according to the manufacturer’s instructions. The quantification of <i>K</i><sub>i</sub>-67 were performed by using the Image Pro.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00441" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00441" class="ext-link">10.1021/acs.jmedchem.8b00441</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>spectra of all new compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Crystallographic information files (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_003.cif" class="ext-link">CIF1</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_004.cif" class="ext-link">CIF2</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_001.pdf">jm8b00441_si_001.pdf (3.79 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_002.csv">jm8b00441_si_002.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_003.cif">jm8b00441_si_003.cif (27.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_004.cif">jm8b00441_si_004.cif (13.33 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00441" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping Sun</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 210009, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5c6cdd6c9d5e5c6d5d08bc0c1d08bc6cb"><span class="__cf_email__" data-cfemail="73101b001f03331003065d1617065d101d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Xie</span> - <span class="hlFld-Affiliation affiliation">Division of Anti-Tumor Pharmacology, the State Key Laboratory of
Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">College
of Pharmacy, University of Chinese Academy
of Sciences, Shanghai, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#93fbebfaf6d3e0fafefebdf2f0bdf0fd"><span class="__cf_email__" data-cfemail="e98191808ca99a808484c7888ac78a87">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ao Zhang</span> - <span class="hlFld-Affiliation affiliation">CAS Key Laboratory of Receptor Research, and the State Key Laboratory
of Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">College
of Pharmacy, University of Chinese Academy
of Sciences, Shanghai, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Technology, ShanghaiTech
University, Shanghai 201210, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7205-9202" title="Orcid link">http://orcid.org/0000-0001-7205-9202</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8eefe1f4e6efe0e9cefde7e3e3a0efeda0ede0"><span class="__cf_email__" data-cfemail="5e3f3124363f30391e2d373333703f3d703d30">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Xue</span> - <span class="hlFld-Affiliation affiliation">CAS Key Laboratory of Receptor Research, and the State Key Laboratory
of Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peiran Song</span> - <span class="hlFld-Affiliation affiliation">Division of Anti-Tumor Pharmacology, the State Key Laboratory of
Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Technology, ShanghaiTech
University, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zilan Song</span> - <span class="hlFld-Affiliation affiliation">CAS Key Laboratory of Receptor Research, and the State Key Laboratory
of Drug Research and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Hefei 230031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linjiang Tong</span> - <span class="hlFld-Affiliation affiliation">Division of Anti-Tumor Pharmacology, the State Key Laboratory of
Drug Research and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">Division of Anti-Tumor Pharmacology, the State Key Laboratory of
Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">College
of Pharmacy, University of Chinese Academy
of Sciences, Shanghai, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Technology, ShanghaiTech
University, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Division of Anti-Tumor Pharmacology, the State Key Laboratory of
Drug Research, 
     and , Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">College
of Pharmacy, University of Chinese Academy
of Sciences, Shanghai, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Technology, ShanghaiTech
University, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy
of Sciences, Hefei 230031, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.X., P.S., and Z.S. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d503e6106-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from Chinese NSF (Grants 81430080, 81773565, 81703327). Supporting grants from the International Cooperative Program (Grant GJHZ1622) and Key Program of the Frontier Science (Grant 160621) of the Chinese Academy of Sciences, the Shanghai Commission of Science and Technology (Grants 16XD1404600, 14431900400), Jiangsu University Excellent Scientific and Technological Innovation Team (2015), as well as Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_0684) are also appreciated.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptor</p></td></tr><tr><td class="NLM_term">RTV</td><td class="NLM_def"><p class="first last">relative tumor volume</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time of maximum concentration</p></td></tr><tr><td class="NLM_term">AUC<sub>0-∞</sub></td><td class="NLM_def"><p class="first last">area under the plasma concentration time curve</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">PLCγ2</td><td class="NLM_def"><p class="first last">phospholipase γ2</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">MesCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last">N-bromobutanimide</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">9-BBN</td><td class="NLM_def"><p class="first last">9-borabicyclo[3.3.1]nonane</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium-3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DACH-naphthyl</td><td class="NLM_def"><p class="first last">1,2-diaminocyclohexane-<i>N</i>,<i>N</i>′-bis(2-diphenyl phosphino-1-naphthoyl)</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">SPF</td><td class="NLM_def"><p class="first last">specific pathogen free</p></td></tr><tr><td class="NLM_term">IHC</td><td class="NLM_def"><p class="first last">immunohistochemical</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span> <span> </span><span class="NLM_article-title">The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+family+of+cytoplasmic+tyrosine+kinases%3A+mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+homologs+in+other+species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0ljPqLOzYcvuGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520family%2520of%2520cytoplasmic%2520tyrosine%2520kinases%253A%2520mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520homologs%2520in%2520other%2520species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The role of Bruton’s tyrosine kinase in B-cell development and function: A genetic perspective</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2000.imr017504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B-cell+development+and+function%3A+A+genetic+perspective&doi=10.1111%2Fj.1600-065X.2000.imr017504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0ljPqLOzYcvuGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520role%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B-cell%2520development%2520and%2520function%253A%2520A%2520genetic%2520perspective%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127%26doi%3D10.1111%2Fj.1600-065X.2000.imr017504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0ljPqLOzYcvuGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humire-Greiff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniar, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjellén, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovský, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+E.+Smithauthor=B.+Baskinauthor=P.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjell%C3%A9nauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstr%C3%B6mauthor=D.+Bentleyauthor=D.+Vetireauthor=K.+B.+Islamauthor=I.+Vorechovsk%C3%BDauthor=P.+Sideras&title=Expression+of+Bruton%E2%80%99s+agammaglobulinemia+tyrosine+kinase+gene%2C+BTK%2C+is+selectively+down-regulated+in+T+lymphocytes+and+plasma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0ljwWEzkw0BgSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjell%25C3%25A9n%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DVetire%26aufirst%3DD.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520agammaglobulinemia%2520tyrosine%2520kinase%2520gene%252C%2520BTK%252C%2520is%2520selectively%2520down-regulated%2520in%2520T%2520lymphocytes%2520and%2520plasma%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of B-cell lymphoma pathogenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1038/nrc1589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=15803153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&author=R.+K%C3%BCppers&title=Mechanisms+of+B-cell+lymphoma+pathogenesis&doi=10.1038%2Fnrc1589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0ljwWEzkw0BgSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-cell%2520lymphoma%2520pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D251%26epage%3D262%26doi%3D10.1038%2Fnrc1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+D.+Yangauthor=W.+H.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+M.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0lhA__RiarPKlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%2BD.%26aulast%3DXu%26aufirst%3DW.%2BH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%2BM.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span> <span> </span><span class="NLM_article-title">B-cell receptor signaling as a driver of lymphoma development and evolution</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2013.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.semcancer.2013.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=24060900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Srsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=410-421&author=C.+U.+Niemannauthor=A.+Wiestner&title=B-cell+receptor+signaling+as+a+driver+of+lymphoma+development+and+evolution&doi=10.1016%2Fj.semcancer.2013.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell receptor signaling as a driver of lymphoma development and evolution</span></div><div class="casAuthors">Niemann, Carsten U.; Wiestner, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6PA</span>),
    <span class="NLM_cas:pages">410-421</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The B-cell receptor (BCR) is essential for normal B-cell development and maturation.  In an increasing no. of B-cell malignancies, BCR signaling is implicated as a pivotal pathway in tumorigenesis.  Mechanisms of BCR activation are quite diverse and range from chronic antigenic drive by microbial or viral antigens to autostimulation of B-cells by self-antigens to activating mutations in intracellular components of the BCR pathway.  Hepatitis C virus infection can lead to the development of splenic marginal zone lymphoma, while Helicobacter pylori infection is assocd. with the development of mucosa-assocd. lymphoid tissue lymphomas.  In some of these cases, successful treatment of the infection removes the inciting antigen and results in resoln. of the lymphoma.  Chronic lymphocytic leukemia has been recognized for decades as a malignancy of auto-reactive B-cells and its clin. course is in part detd. by the differential response of the malignant cells to BCR activation.  In a no. of B-cell malignancies, activating mutations in signal transduction components of the BCR pathway have been identified; prominent examples are activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) that carry mutations in CD79B and CARD11 and display chronic active BCR signaling resulting in constitutive activation of the NF-κB pathway.  Despite considerable heterogeneity in biol. and clin. course, many mature B-cell malignancies are highly sensitive to kinase inhibitors that disrupt BCR signaling.  Thus, targeted therapy through inhibition of BCR signaling is emerging as a new treatment paradigm for many B-cell malignancies.  Here, we review the role of the BCR in the pathogenesis of B-cell malignancies and summarize clin. results of the emerging class of kinase inhibitors that target this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4y2VaqCqOLVg90H21EOLACvtfcHk0lhA__RiarPKlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Srsb3F&md5=2ff0932e4c270986282ada8a9c6f453e</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2013.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2013.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DB-cell%2520receptor%2520signaling%2520as%2520a%2520driver%2520of%2520lymphoma%2520development%2520and%2520evolution%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D410%26epage%3D421%26doi%3D10.1016%2Fj.semcancer.2013.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Y.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lhA__RiarPKlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Y.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhqY5wKTsWeNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib (PCI-32765), the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trials</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s11899-012-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1007%2Fs11899-012-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=23296407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1-6&author=J.+R.+Brown&title=Ibrutinib+%28PCI-32765%29%2C+the+first+BTK+%28Bruton%E2%80%99s+tyrosine+kinase%29+inhibitor+in+clinical+trials&doi=10.1007%2Fs11899-012-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials</span></div><div class="casAuthors">Brown Jennifer R</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib is a potent covalent kinase inhibitor that targets BTK.  BTK, or Bruton's tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia.  Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment.  As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and response associated with rapid increase in lymphocytosis, which then returns to baseline over time.  The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months.  In a cohort of untreated patients 65 years and over, the estimated 15 month PFS is 96 %.  Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmwv_ITNl9Dxgd2Wuil24tfW6udTcc2eZq2bCs7gs9Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D&md5=c64d7d8fa5d40a79ad029c9fb34248c3</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-012-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-012-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%2520%2528PCI-32765%2529%252C%2520the%2520first%2520BTK%2520%2528Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2529%2520inhibitor%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2013%26volume%3D8%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs11899-012-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4d093f382a0d0b090c">[email protected]</a>, New Drug Application
2055520 Pharmacology Review(s).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug%40FDA%2C+New+Drug+Application%0A2055520+Pharmacology+Review%28s%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s40266-017-0468-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1007%2Fs40266-017-0468-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=28536906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=509-527&author=A.+Awauthor=J.+R.+Brown&title=Current+status+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+development+and+use+in+B-cell+malignancies&doi=10.1007%2Fs40266-017-0468-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies</span></div><div class="casAuthors">Aw, Andrew; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">509-527</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The B-cell receptor (BCR) pathway plays an important role in the survival, proliferation and trafficking of cancer cells in a variety of B-cell malignancies.  Recently, a no. of agents have been developed to target various components of the BCR pathway.  One such target is Bruton's tyrosine kinase (BTK), a Tec family kinase member found near the cell membrane that is involved in upstream BCR signaling.  The biol. function of BTK in several B-cell lymphoid malignancies has led to the development of the oral BTK inhibitor ibrutinib.  In chronic lymphocytic leukemia (CLL), ibrutinib has demonstrated durable clin. responses in relapsed/refractory (R/R) patients, including those with the high-risk del(17p) cytogenetic abnormality.  These findings have paved the way for trials evaluating ibrutinib in previously untreated CLL patients, and also in combination with chemoimmunotherapy or other novel agents.  Durable clin. responses have also been demonstrated in mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia (WM) patients treated with ibrutinib.  Ibrutinib is generally well tolerated, although current follow-up remains short and patients of advanced age are more likely to discontinue treatment for toxicity.  Treatment-specific side effects such as bleeding and atrial fibrillation may, at least partly, be related to off-target inhibition of non-BTK kinases.  Studies evaluating other potential indications for BTK inhibition are ongoing, including in post-allogeneic hematopoietic stem cell transplant patients for whom ibrutinib may be effective in modulating graft-vs.-host disease.  Combination trials of ibrutinib with venetoclax, a Bcl-2 inhibitor, are underway and are supported by sound preclin. rationale.  Several next-generation BTK inhibitors are under development with the goal of decreasing treatment-related toxicity and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6yK1USSJm3bVg90H21EOLACvtfcHk0lhqY5wKTsWeNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVSqtb4%253D&md5=24f1451099e7af18962a5778df3dea35</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40266-017-0468-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-017-0468-4%26sid%3Dliteratum%253Aachs%26aulast%3DAw%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DCurrent%2520status%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520development%2520and%2520use%2520in%2520B-cell%2520malignancies%26jtitle%3DDrugs%2520Aging%26date%3D2017%26volume%3D34%26spage%3D509%26epage%3D527%26doi%3D10.1007%2Fs40266-017-0468-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-86&author=J.+J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+L.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0lhSHjtMHvaN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D86%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21-25&author=J.+J.+Wuauthor=M.+Z.+Zhangauthor=D.+L.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0lhSHjtMHvaN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DM.%2BZ.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26epage%3D25%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montraveta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Jensen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2841</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1158%2F1078-0432.CCR-16-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=27903679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2831-2841&author=S.+E.+M.+Hermanauthor=A.+Montravetaauthor=C.+U.+Niemannauthor=H.+Mora-Jensenauthor=M.+Gulrajaniauthor=F.+Krantzauthor=R.+Mantelauthor=L.+L.+Smithauthor=F.+McClanahanauthor=B.+K.+Harringtonauthor=D.+Colomerauthor=T.+Coveyauthor=J.+C.+Byrdauthor=R.+Izumiauthor=A.+Kapteinauthor=R.+Ulrichauthor=A.+J.+Johnsonauthor=B.+J.+Lannuttiauthor=A.+Wiestnerauthor=J.+A.+Woyach&title=The+Bruton+tyrosine+kinase+%28BTK%29+inhibitor+acalabrutinib+demonstrates+potent+on-target+effects+and+efficacy+in+two+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.CCR-16-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">Herman, Sarah E. M.; Montraveta, Arnau; Niemann, Carsten U.; Mora-Jensen, Helena; Gulrajani, Michael; Krantz, Fanny; Mantel, Rose; Smith, Lisa L.; McClanahan, Fabienne; Harrington, Bonnie K.; Colomer, Dolors; Covey, Todd; Byrd, John C.; Izumi, Raquel; Kaptein, Allard; Ulrich, Roger; Johnson, Amy J.; Lannutti, Brian J.; Wiestner, Adrian; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2841</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK.  We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL).  Exptl. Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model.  Mice received either vehicle or acalabrutinib formulated into the drinking water.  Results: Utilizing biochem. assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib.  In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLCγ2, ERK, and significant inhibition of CLL cell proliferation.  Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice.  Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLCγ2, and S6 was obsd.  Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle.  Conclusions: Treatment with acalabrutinib potently inhibits BTK in vivo, leading to on-target decreases in the activation of key signaling mols. (including BTK, PLCγ2, S6, and ERK).  In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment.  Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy in vivo on par with ibrutinib.  Clin Cancer Res; 23(11); 2831-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD7ESW1IqIY7Vg90H21EOLACvtfcHk0lhSHjtMHvaN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D&md5=a3c89f6918d1ed1195f4d439f33c17d7</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DMontraveta%26aufirst%3DA.%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DMcClanahan%26aufirst%3DF.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DWiestner%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520acalabrutinib%2520demonstrates%2520potent%2520on-target%2520effects%2520and%2520efficacy%2520in%2520two%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2831%26epage%3D2841%26doi%3D10.1158%2F1078-0432.CCR-16-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuhiro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 2452: ONO-4059, a novel oral Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2452</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-2452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1158%2F1538-7445.AM2013-2452" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2452&author=T.+Yasuhiroauthor=T.+Yoshizawaauthor=S.+Hottaauthor=Y.+Arizaauthor=Y.+Uedaauthor=R.+Kozakiauthor=J.+Birkett&title=Abstract+2452%3A+ONO-4059%2C+a+novel+oral+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor+that+demonstrates+potent+pharmacodynamic+activity+through+Phosphorylated+Btk+%28P-Btk%29+inhibition%2C+in+addition+to+effective+anti-tumour+activity+in+a+TMD-8+%28DLBCL%29+xenograft+model&doi=10.1158%2F1538-7445.AM2013-2452"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-2452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-2452%26sid%3Dliteratum%253Aachs%26aulast%3DYasuhiro%26aufirst%3DT.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DS.%26aulast%3DAriza%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DKozaki%26aufirst%3DR.%26aulast%3DBirkett%26aufirst%3DJ.%26atitle%3DAbstract%25202452%253A%2520ONO-4059%252C%2520a%2520novel%2520oral%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%2520that%2520demonstrates%2520potent%2520pharmacodynamic%2520activity%2520through%2520Phosphorylated%2520Btk%2520%2528P-Btk%2529%2520inhibition%252C%2520in%2520addition%2520to%2520effective%2520anti-tumour%2520activity%2520in%2520a%2520TMD-8%2520%2528DLBCL%2529%2520xenograft%2520model%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2452%26doi%3D10.1158%2F1538-7445.AM2013-2452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0ljFmO3tE5ZJyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BTK with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+D.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+BTK+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljFmO3tE5ZJyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%2BD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520BTK%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+L.+Wangauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furmanauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lhdGvC9uH6t9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) Inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+C.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+Inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0limf1A81hytjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%2BC.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0limf1A81hytjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+M.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Q.+Weiauthor=K.+Reifauthor=L.+C.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+a+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0ljsmQETxR56wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%2BM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%2BC.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0ljsmQETxR56wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of a small molecule inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-based+discovery+of+a+small+molecule+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lhyTrmCqm5jCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-based%2520discovery%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5112</span>– <span class="NLM_lpage">5128</span>, <span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+T.+Liauthor=Y.+Y.+Zuoauthor=G.+H.+Tangauthor=Y.+Wangauthor=Y.+Q.+Zhouauthor=X.+Y.+Wangauthor=T.+L.+Guoauthor=M.+Y.+Xiaauthor=N.+Dingauthor=Z.+Y.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0lhyTrmCqm5jCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BT.%26aulast%3DZuo%26aufirst%3DY.%2BY.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DT.%2BL.%26aulast%3DXia%26aufirst%3DM.%2BY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydro quinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+J.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+H.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.+R.+Wuauthor=C.+L.+Wangauthor=Y.+R.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+H.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+F.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydro+quinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%2BJ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BR.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydro%2520quinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Bruton’s tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2012.01415.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1111%2Fj.1747-0285.2012.01415.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=22594639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=366-373&author=H.+L.+Wanauthor=Z.+R.+Wangauthor=L.+L.+Liauthor=C.+Chengauthor=P.+Jiauthor=J.+J.+Liuauthor=H.+Zhangauthor=J.+Zouauthor=S.+Y.+Yang&title=Discovery+of+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+using+a+hybrid+protocol+of+virtual+screening+approaches+based+on+SVM+model%2C+pharmacophore+and+molecular+docking&doi=10.1111%2Fj.1747-0285.2012.01415.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking</span></div><div class="casAuthors">Wan, Hua-Lin; Wang, Ze-Rong; Li, Lin-Li; Cheng, Chuan; Ji, Pan; Liu, Jing-Jing; Zhang, Hui; Zou, Jun; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-373</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase has emerged as a potential target for the treatment for B-cell malignancies and autoimmune diseases.  Discovery of Bruton's tyrosine kinase inhibitors has thus attracted much attention recently.  In this investigation, we introduced a hybrid protocol of virtual screening methods including support vector machine model-based virtual screening, pharmacophore model-based virtual screening and docking-based virtual screening for retrieving new Bruton's tyrosine kinase inhibitors from com. available chem. databases.  Performances of the hybrid virtual screening approach were evaluated against a test set, which results showed that the hybrid virtual screening approach significantly shortened the overall screening time, and considerably increased the hit rate and enrichment factor compared with the individual method (SB-VS, PB-VS and DB-VS) or their combinations by twos.  This hybrid virtual screening approach was then applied to screen several chem. databases including Specs (202 408 compds.) and Enamine (980 000 compds.) databases.  Thirty-nine compds. were selected from the final hits and have been shifted to exptl. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWM-iX39A7ebVg90H21EOLACvtfcHk0ljPq5jyKHFoIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbfN&md5=eedf54c120aa2e10d2f87625d0bee570</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2012.01415.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2012.01415.x%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520using%2520a%2520hybrid%2520protocol%2520of%2520virtual%2520screening%2520approaches%2520based%2520on%2520SVM%2520model%252C%2520pharmacophore%2520and%2520molecular%2520docking%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2012%26volume%3D80%26spage%3D366%26epage%3D373%26doi%3D10.1111%2Fj.1747-0285.2012.01415.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Nonoshita, K.</span>; <span class="NLM_string-name">Shimamura, T.</span></span> <span> </span><span class="NLM_article-title">Novel Quinolone-substituted Compound</span>. <span class="NLM_patent">WO 2015/025936 A1</span>, February 26, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Uno&author=K.+Nonoshita&author=T.+Shimamura&title=Novel+Quinolone-substituted+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DT.%26atitle%3DNovel%2520Quinolone-substituted%2520Compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of pyrazolo[3,4-<i>d</i>]pyrimidines as tyrosine kinase RET inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2544</span>– <span class="NLM_lpage">2548</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.bmcl.2017.03.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2544-2548&author=C.+Y.+Wangauthor=H.+C.+Liuauthor=Z.+L.+Songauthor=Y.+C.+Jiauthor=L.+Xingauthor=X.+Pengauthor=X.+S.+Wangauthor=J.+Aiauthor=M.+Y.+Gengauthor=A.+Zhang&title=Synthesis+and+structure-activity+relationship+study+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+as+tyrosine+kinase+RET+inhibitors&doi=10.1016%2Fj.bmcl.2017.03.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.088%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BC.%26aulast%3DSong%26aufirst%3DZ.%2BL.%26aulast%3DJi%26aufirst%3DY.%2BC.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520tyrosine%2520kinase%2520RET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2544%26epage%3D2548%26doi%3D10.1016%2Fj.bmcl.2017.03.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0ljPq5jyKHFoIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Konteatis, Z.</span>; <span class="NLM_string-name">Moffett, K.</span>; <span class="NLM_string-name">Lee, Y.
H.</span>; <span class="NLM_string-name">Chao, W.
C.</span></span> Pyrrolotriazine Compounds. <span class="NLM_patent">WO 2010/126960 A1</span>, November 4, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Konteatis%2C+Z.%3B+Moffett%2C+K.%3B+Lee%2C+Y.%0AH.%3B+Chao%2C+W.%0AC.+Pyrrolotriazine+Compounds.+WO+2010%2F126960+A1%2C+November+4%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKonteatis%26aufirst%3DZ.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span>; <span class="NLM_string-name">Conlon, P.</span>; <span class="NLM_string-name">Erlanson, D. A.</span>; <span class="NLM_string-name">Fan, J. F.</span>; <span class="NLM_string-name">Guan, B.</span>; <span class="NLM_string-name">Hopkins, B. T.</span>; <span class="NLM_string-name">Ishchenko, A.</span>; <span class="NLM_string-name">Jenkins, T. J.</span>; <span class="NLM_string-name">Kumaravel, G.</span>; <span class="NLM_string-name">Marcotte, D.</span>; <span class="NLM_string-name">Powell, N.</span>; <span class="NLM_string-name">Scott, D.</span>; <span class="NLM_string-name">Taveras, A.</span>; <span class="NLM_string-name">Wang, D. P.</span>; <span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl Btk Inhibitors</span>. <span class="NLM_patent">WO 2011/029043 A1</span>, March 10, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Bui&author=P.+Conlon&author=D.+A.+Erlanson&author=J.+F.+Fan&author=B.+Guan&author=B.+T.+Hopkins&author=A.+Ishchenko&author=T.+J.+Jenkins&author=G.+Kumaravel&author=D.+Marcotte&author=N.+Powell&author=D.+Scott&author=A.+Taveras&author=D.+P.+Wang&author=M.+Zhong&title=Heteroaryl+Btk+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26atitle%3DHeteroaryl%2520Btk%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span>; <span class="NLM_string-name">Seenisamy, J.</span>; <span class="NLM_string-name">Liu-Bujalski, L.</span>; <span class="NLM_string-name">Potnick, J.</span>; <span class="NLM_string-name">Caldwell, R. D.</span>; <span class="NLM_string-name">Qiu, H.</span>; <span class="NLM_string-name">Neagu, C.</span>; <span class="NLM_string-name">Jones, R.</span>; <span class="NLM_string-name">Won, A. C.</span>; <span class="NLM_string-name">Goutopoulos, A.</span>; <span class="NLM_string-name">Sherer, B. A.</span>; <span class="NLM_string-name">Johnson, T. L.</span>; <span class="NLM_string-name">Gardberg, A.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl Compounds as Btk Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2016/057500 A1</span>, April 14, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Gaillard&author=J.+Seenisamy&author=L.+Liu-Bujalski&author=J.+Potnick&author=R.+D.+Caldwell&author=H.+Qiu&author=C.+Neagu&author=R.+Jones&author=A.+C.+Won&author=A.+Goutopoulos&author=B.+A.+Sherer&author=T.+L.+Johnson&author=A.+Gardberg&title=Heteroaryl+Compounds+as+Btk+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaillard%26aufirst%3DP.%26atitle%3DHeteroaryl%2520Compounds%2520as%2520Btk%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Lu, Z. J.</span>; <span class="NLM_string-name">Zhou, Y. B.</span>; <span class="NLM_string-name">Gao, A. H.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors</span>. <span class="NLM_patent">WO 2017/127371 A1</span>, July 27, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+B.+Liao&author=J.+Li&author=Z.+J.+Lu&author=Y.+B.+Zhou&author=A.+H.+Gao&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DX.%2BB.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of thieno[3,2-<i>c</i>]pyridin-4-amines as novel Bruton’s tyrosine kinase (BTK) inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6059</span>– <span class="NLM_lpage">6068</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.bmc.2015.05.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26277759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6059-6068&author=X.+G.+Zhaoauthor=M.+H.+Xinauthor=Y.+Z.+Wangauthor=W.+Huangauthor=Q.+Jinauthor=F.+Tangauthor=G.+Wuauthor=Y.+Zhaoauthor=H.+Xiang&title=Discovery+of+thieno%5B3%2C2-c%5Dpyridin-4-amines+as+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors&doi=10.1016%2Fj.bmc.2015.05.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors</span></div><div class="casAuthors">Zhao, Xinge; Xin, Minhang; Wang, Yazhou; Huang, Wei; Jin, Qiu; Tang, Feng; Wu, Gang; Zhao, Yong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6059-6068</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of BTK inhibitors bearing thieno[3,2-c]pyridin-4-amine framework as the core scaffold were designed, synthesized and well characterized.  In this paper, twenty one compds. displayed variant inhibitory activities against BTK in vitro, and compd. 14g showed the most potent inhibitory activity against BTK enzyme, with the IC50 value of 12.8 nM.  Moreover, compds. 14g displayed relatively good kinase selectivity and was subsequently evaluated in vivo for profiling its PK properties.  This work identified the thieno[3,2-c]pyridin-4-amine derivs. as novel BTK inhibitors and verified the value of thieno[3,2-c]pyridin-4-amine scaffold in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgi2j2x_zAQLVg90H21EOLACvtfcHk0ljbtuaPagNf4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsb8%253D&md5=00266a30edeab1875d7321b6c230ae02</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.043%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%2BG.%26aulast%3DXin%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BZ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520thieno%255B3%252C2-c%255Dpyridin-4-amines%2520as%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6059%26epage%3D6068%26doi%3D10.1016%2Fj.bmc.2015.05.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiadeen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krikorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raaijmakers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu-Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-<i>a</i>]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+L.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.+B.+Alhassanauthor=Y.+N.+Yuauthor=H.+Vaccaroauthor=S.+L.+Liuauthor=C.+D.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=J.+de+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.+D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Mansuetoauthor=Z.+W.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20fR"><div class="casContent"><span class="casTitleNuber">20f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Liu, Jian; Guiadeen, Deodial; Krikorian, Arto; Gao, Xiaolei; Wang, James; Boga, Sobhana Babu; Alhassan, Abdul-Basit; Yu, Younong; Vaccaro, Henry; Liu, Shilan; Yang, Chundao; Wu, Hao; Cooper, Alan; de Man, Jos; Kaptein, Allard; Maloney, Kevin; Hornak, Viktor; Gao, Ying-Duo; Fischmann, Thierry O.; Raaijmakers, Hans; Vu-Pham, Diep; Presland, Jeremy; Mansueto, My; Xu, Zangwei; Leccese, Erica; Zhang-Hoover, Jie; Knemeyer, Ian; Garlisi, Charles G.; Bays, Nathan; Stivers, Peter; Brandish, Philip E.; Hicks, Alexandra; Kim, Ronald; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway.  It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases.  We report a series of compds. based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity.  Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket.  These interactions are evident in the X-ray crystal structure of the lead compds. 1 and 3 in the complex with the BTK enzyme.  Our lead compds. show desirable PK profiles and efficacy in the preclin. rat collagen induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNSbzZ9EmurVg90H21EOLACvtfcHk0ljbtuaPagNf4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ&md5=62031c18108d12d36cb7f8e3c35888b7</span></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.%2BB.%26aulast%3DYu%26aufirst%3DY.%2BN.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DMansueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%2BW.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljLwttCsKgL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1002/cpt.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fcpt.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=25669675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=455-468&author=Y.+Wangauthor=L.+L.+Zhangauthor=R.+E.+Champlinauthor=M.+L.+Wang&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+with+ibrutinib+in+B-cell+malignancies&doi=10.1002%2Fcpt.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies</span></div><div class="casAuthors">Wang, Y.; Zhang, L. L.; Champlin, R. E.; Wang, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-468</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The B-cell receptor signaling pathway, which is crit. to the development and maturation of normal B-cells, is emerging as an attractive therapeutic target in B-cell malignancies.  Ibrutinib is a potent irreversible inhibitor of Bruton's tyrosine kinase (Btk), a key kinase important for signal transduction in the B-cell receptor (BCR) pathway.  In preclin. studies, ibrutinib potently bound to Btk, inhibited BCR signaling, and decreased tumor cell proliferation and survival in many B-cell malignancy models.  Excellent safety and efficacy data in clin. trials have led to US Food and Drug Administration (FDA) approval of ibrutinib for previously treated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), as well as CLL with 17p deletion.  Ongoing clin. studies have also demonstrated great potency of ibrutinib in treating other types of non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Waldenstroem's macroglobulinemia (WM).  Combination of ibrutinib with chemoimmunotherapy and other promising novel agents in B-cell malignancy therapy has also been under clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4WL6Xb_Qdq7Vg90H21EOLACvtfcHk0ljLwttCsKgL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWisLk%253D&md5=f74d5fa50e5d8dd9689699f64646eb0b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcpt.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.85%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%2BL.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DWang%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520ibrutinib%2520in%2520B-cell%2520malignancies%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D97%26spage%3D455%26epage%3D468%26doi%3D10.1002%2Fcpt.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholzen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdes, J.</span></span> <span> </span><span class="NLM_article-title">The Ki-67 protein: from the known and the unknown</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10653597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=311-322&author=T.+Scholzenauthor=J.+Gerdes&title=The+Ki-67+protein%3A+from+the+known+and+the+unknown&doi=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Ki-67 protein: from the known and the unknown</span></div><div class="casAuthors">Scholzen, Thomas; Gerdes, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-322</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review with 95 refs.  The expression of the human Ki-67 protein is strictly assocd. with cell proliferation.  During interphase, the antigen can be exclusively detected within the nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes.  The fact that the Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells (Go), makes it an excellent marker for detg. the so-called growth fraction of a given cell population.  In the first part of this study, the term Proliferation marker is discussed and examples of the applications of anti-Ki-67 protein antibodies in diagnostics of human tumors are given.  The fraction of Ki-67-pos. tumor cells (the Ki-67 labeling index) is often correlated with the clin. course of the disease.  The best-studied examples in this context are carcinomas of the prostate and the breast.  For these types of tumors, the prognostic value for survival and tumor recurrence has repeatedly been proven in uni- and multivariate anal.  The prepn. of new monoclonal antibodies that react with the Ki-67 equiv protein from rodents now extends the use of the Ki-67 protein as a proliferation marker to lab. animals that are routinely used in basic research.  The second part of this review focuses on the biol. of the Ki-67 protein.  Our current knowledge of the Ki-67 gene and protein structure, mRNA splicing, expression, and cellular localization during the cell-division cycle is summarized and discussed.  Although the Ki-67 protein is well characterized on the mol. level and extensively used as a proliferation marker, the functional significance still remains unclear.  There are indications, however, that Ki-67 protein expression is an abs. requirement for progression through the cell-division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH90qONVnezrVg90H21EOLACvtfcHk0liZahiXBBPQ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Ggsg%253D%253D&md5=8ff8ab674303ccf7d324ca3c770eeb8a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4652%2528200003%2529182%253A3%253C311%253A%253AAID-JCP1%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DScholzen%26aufirst%3DT.%26aulast%3DGerdes%26aufirst%3DJ.%26atitle%3DThe%2520Ki-67%2520protein%253A%2520from%2520the%2520known%2520and%2520the%2520unknown%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2000%26volume%3D182%26spage%3D311%26epage%3D322%26doi%3D10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameriks, M. K.</span></span> <span> </span><span class="NLM_article-title">Development of a flexible strategy towards FR900482 and the mitomycins</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7890</span>– <span class="NLM_lpage">7903</span>, <span class="refDoi"> DOI: 10.1002/chem.201003489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fchem.201003489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=21618622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7890-7903&author=B.+M.+Trostauthor=B.+M.+O%E2%80%99Boyleauthor=W.+Torresauthor=M.+K.+Ameriks&title=Development+of+a+flexible+strategy+towards+FR900482+and+the+mitomycins&doi=10.1002%2Fchem.201003489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Flexible Strategy towards FR 900482 and the Mitomycins</span></div><div class="casAuthors">Trost, Barry M.; O'Boyle, Brendan M.; Torres, Wildeliz; Ameriks, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7890-7903, S7890/1-S7890/136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">FR 900482 (I) and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biol. mechanisms and obvious structural similarity.  Both classes possess potent anticancer activity, a feature that has led to their investigation and implementation for the clin. treatment of human cancer.  Given the structural similarity between these natural products, we envisioned a common synthetic strategy by which both classes could be targeted through assembling the mitomycin skeleton prior to further oxidative functionalization.  Realization of this strategy with respect to FR 900482 was accomplished through the synthesis of 7-epi-FR 900482, which displayed equal potency relative to the natural product against two human cancer cell lines.  With the challenging goal of a synthesis of either mitomycin or FR 900482 in mind, several methodologies were explored.  While not all of these methods ultimately proved useful for our synthetic goal, a no. of them led to intriguing findings that provide a more complete understanding of several methodologies.  In particular, amination via π-allyl palladium complexes for the synthesis of tetrahydroquinolines, eight-membered heterocycle formation via carbonylative lactamization, and amination through late-stage C-H insertion via rhodium catalysis all featured prominently in our synthetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ735AhxJdT7Vg90H21EOLACvtfcHk0liZahiXBBPQ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslKmtLY%253D&md5=45504b5f1d935cd3a145f11f9aa434ca</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fchem.201003489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201003489%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DB.%2BM.%26aulast%3DTorres%26aufirst%3DW.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26atitle%3DDevelopment%2520of%2520a%2520flexible%2520strategy%2520towards%2520FR900482%2520and%2520the%2520mitomycins%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2011%26volume%3D17%26spage%3D7890%26epage%3D7903%26doi%3D10.1002%2Fchem.201003489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span>; <span class="NLM_string-name">Gao, Y. X.</span>; <span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Ni, H. H.</span>; <span class="NLM_string-name">Mulvihill, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Nicotinimide Inhibitors of Btk and Their Preparation and Use in the Treatment of Cancer, Inflammation and Autoimmune Disease</span>. <span class="NLM_patent">WO 2015/048662 A2</span>, April 2, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=X.+Y.+Chen&author=Y.+X.+Gao&author=C.+Liu&author=H.+H.+Ni&author=M.+Mulvihill&title=Substituted+Nicotinimide+Inhibitors+of+Btk+and+Their+Preparation+and+Use+in+the+Treatment+of+Cancer%2C+Inflammation+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BY.%26atitle%3DSubstituted%2520Nicotinimide%2520Inhibitors%2520of%2520Btk%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%252C%2520Inflammation%2520and%2520Autoimmune%2520Disease%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c','cit17d'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d','cit20e','cit20f'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6561-6574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Aminoquinoline-3-carboxamide%252BDerivatives%252Bas%252BPotent%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DYao%26aufirst%3DXia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D12072019%26date%3D01072019%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiakuo  Liu</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dongmei  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113329. <a href="https://doi.org/10.1016/j.ejmech.2021.113329" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113329%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEmerging%252Bsmall-molecule%252Binhibitors%252Bof%252Bthe%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%25253A%252BCurrent%252Bdevelopment%26aulast%3DLiu%26aufirst%3DJiakuo%26date%3D2021%26volume%3D217%26spage%3D113329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhenbang  Li</span>, <span class="hlFld-ContribAuthor ">Yumei  Zou</span>, <span class="hlFld-ContribAuthor ">Shengnan  Ren</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112339. <a href="https://doi.org/10.1016/j.ejmech.2020.112339" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112339%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bhighly%252Bselective%252Bcovalent%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Bbearing%252Btriazine%252Bscaffold%26aulast%3DTeng%26aufirst%3DYu%26date%3D2020%26volume%3D199%26spage%3D112339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jarosław  Sączewski</span>, <span class="hlFld-ContribAuthor ">Joanna  Fedorowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Three Heterocyclic Rings Fused (6-5-6). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14881-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14881-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14881-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14881-4%26sid%3Dliteratum%253Aachs%26atitle%3DThree%252BHeterocyclic%252BRings%252BFused%252B%2525286-5-6%252529%26aulast%3DS%25C4%2585czewski%26aufirst%3DJaros%25C5%2582aw%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aimen K.  Aljoundi</span>, <span class="hlFld-ContribAuthor ">Clement  Agoni</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Mahmoud E.S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (11)
                                     , 1325-1339. <a href="https://doi.org/10.2174/1871520619666190405111526" title="DOI URL">https://doi.org/10.2174/1871520619666190405111526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190405111526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190405111526%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DTurning%252Bto%252BComputer-aided%252BDrug%252BDesign%252Bin%252Bthe%252BTreatment%252Bof%252BDiffuse%252BLarge%252BB-cell%252BLymphoma%25253A%252BHas%252Bit%252Bbeen%252BHelpful%25253F%26aulast%3DAljoundi%26aufirst%3DAimen%2BK.%26date%3D2019%26volume%3D19%26issue%3D11%26spage%3D1325%26epage%3D1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Dou  Dou</span>, <span class="hlFld-ContribAuthor ">Yingqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3390-3395. <a href="https://doi.org/10.1016/j.bmc.2019.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252Bevaluation%252Bof%252Bpyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-dione%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DDiao%26aufirst%3DYanyan%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3390%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyu  Li</span>, <span class="hlFld-ContribAuthor ">Binyu  Shi</span>, <span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Huizhu  Yang</span>, <span class="hlFld-ContribAuthor ">Jiurong  Li</span>, <span class="hlFld-ContribAuthor ">Lianjian  Wang</span>, <span class="hlFld-ContribAuthor ">Siying  He</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 294-299. <a href="https://doi.org/10.1039/C8MD00413G" title="DOI URL">https://doi.org/10.1039/C8MD00413G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00413G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00413G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2-phenyl%252Bpyrimidine%252Bderivatives%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DLi%26aufirst%3DXinyu%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D294%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical BTK inhibitors <b>1</b>–<b>4</b> (A) and our design of new BTK inhibitors <b>I</b> and <b>II</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding modes of compounds <b>1</b> (A), <b>5</b> (B), and <b>7</b> (C) with BTK (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterizations of compounds <b>5</b>–<b>7</b> as potent BTK inhibitors. (A) Chemical structures of <b>5</b>–<b>7</b>. (B) In vitro kinase inhibitory activities of compounds against wild-type BTK. (C) In vitro kinase inhibitory activities of compounds <b>7</b> and <b>1</b> against BTK<sup>C481S</sup> mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Human kinome wide selectivity profiling of compounds <b>5</b> and <b>7</b> in DiscoveRx KINOMEScan screening platform. Measurements were performed at 1 μM concentration of the compounds. Upper panel: TREE<i>spot</i> interaction maps for <b>5</b> and <b>7</b> in 468 kinase targets. Lower panel: S-scores of <b>5</b> and <b>7</b> with percent control numbers less than 35, 10, and 1, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A, B) Metabolic study of compounds <b>7S</b> and <b>13S</b> in liver microsomes of different species.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Covalent docking mode of compound <b>7S</b> (green) with BTK (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>) overlapping with <b>1</b> (purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compound <b>7S</b> on TMD8 cells. (A) Inhibitory activity of <b>7S</b> on BTK and downstream signaling pathway in cells. Cells were starved in serum-free medium before treated with the indicated concentrations of compound <b>7S</b> or <b>1</b> for 4 h and stimulated by anti-IGM. (B) Washout experiment of <b>7S</b> in TMD8 cells. (C) Effects of <b>7S</b> on cell cycle in TMD8 cells. (D) <b>7S</b> induced apoptosis of TMD8 cells. Data are shown as mean ± SD. Each experiment was conducted independently three times. *<i>P</i> < 0.05, **<i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo TMD8 xenograft model study of compound <b>7S</b> and <b>1</b>. (A) The tumor growth curve of four groups, including vehicle control, <b>1</b> (25 mg/kg, QD), <b>7S</b> (5 mg/kg, QD), and <b>7S</b> (15 mg/kg, QD). The vehicle group was euthanized on day 13 of treatment, and the other three groups were executed on day 17 of treatment. (B) The body weights of the group mice over time. (C) Inhibition of target (BTK and PLCγ2) activation by <b>7S</b> in tumors. (D) Immunohistochemical analysis of <i>K</i><sub>i</sub>-67 in tumor tissues. *<i>P</i> < 0.05 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) MesCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 85%; (b) K<sub>2</sub>CO<sub>3</sub>, DMF, N<sub>2</sub>, 55 °C, 74%; (c) NH<sub>3</sub>·H<sub>2</sub>O, 1,4-dioxane, 120 °C, seal tube, 75%; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, 90 °C, 71%; (e) NBS, DMF, rt, 84%; (f) (1) 9-BBN, anhydrous THF, N<sub>2</sub>, 0 °C to rt; (2) PdCl<sub>2</sub>dppf, NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 49% (two steps); (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 58% (two steps); (i) propanoic acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 73% (two steps).</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>7</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 88%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 98%; (c) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 45% (two steps); (d) R<sup>4</sup>-COOH, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 66–91% (two steps).</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the <i>R</i>- or <i>S</i>-Isomers of Compounds <b>5</b>, <b>7</b> and <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(C<sub>3</sub>H<sub>5</sub>)<sub>2</sub>Cl<sub>2</sub>, (<i>S</i>,<i>S</i>)-DACH-naphthyl Trost ligand for <b>34R</b> and (<i>R</i>,<i>R</i>)-DACH-naphthyl Trost ligand for <b>34S</b>, Na<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, N<sub>2</sub>, rt, yield 92%, <i>ee</i> 98%; (b) 1) NH<sub>2</sub>CH<sub>3</sub>, open to air, 60 °C; 2) Boc<sub>2</sub>O, NaHCO<sub>3</sub>, ethyl acetate, 88% (two steps).</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/medium/jm-2018-004414_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Chiral Compounds <b>16</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.8b00441/20180517/images/large/jm-2018-004414_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00441&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O, N<sub>2</sub>, 90 °C, 61–85%; (b) NBS, DMF, rt, 70–77%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub> (for <b>16</b>-<b>19</b>) or PdCl<sub>2</sub>dppf (for <b>20</b>-<b>24</b>), NaOH, THF/H<sub>2</sub>O, N<sub>2</sub>, 85 °C, 53–81%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) acrylic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 45–79% (two steps).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span> <span> </span><span class="NLM_article-title">The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+family+of+cytoplasmic+tyrosine+kinases%3A+mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+homologs+in+other+species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0lg9FR6DEyEcuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520family%2520of%2520cytoplasmic%2520tyrosine%2520kinases%253A%2520mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520homologs%2520in%2520other%2520species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The role of Bruton’s tyrosine kinase in B-cell development and function: A genetic perspective</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2000.imr017504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B-cell+development+and+function%3A+A+genetic+perspective&doi=10.1111%2Fj.1600-065X.2000.imr017504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0lh8MFEpzFWTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520role%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B-cell%2520development%2520and%2520function%253A%2520A%2520genetic%2520perspective%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127%26doi%3D10.1111%2Fj.1600-065X.2000.imr017504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lh8MFEpzFWTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humire-Greiff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniar, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjellén, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovský, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+E.+Smithauthor=B.+Baskinauthor=P.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjell%C3%A9nauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstr%C3%B6mauthor=D.+Bentleyauthor=D.+Vetireauthor=K.+B.+Islamauthor=I.+Vorechovsk%C3%BDauthor=P.+Sideras&title=Expression+of+Bruton%E2%80%99s+agammaglobulinemia+tyrosine+kinase+gene%2C+BTK%2C+is+selectively+down-regulated+in+T+lymphocytes+and+plasma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0lh8MFEpzFWTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjell%25C3%25A9n%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DVetire%26aufirst%3DD.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520agammaglobulinemia%2520tyrosine%2520kinase%2520gene%252C%2520BTK%252C%2520is%2520selectively%2520down-regulated%2520in%2520T%2520lymphocytes%2520and%2520plasma%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of B-cell lymphoma pathogenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1038/nrc1589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=15803153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&author=R.+K%C3%BCppers&title=Mechanisms+of+B-cell+lymphoma+pathogenesis&doi=10.1038%2Fnrc1589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0liZBFDDGLQl0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-cell%2520lymphoma%2520pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D251%26epage%3D262%26doi%3D10.1038%2Fnrc1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+D.+Yangauthor=W.+H.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+M.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B-cell-receptor+signalling+in+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0liZBFDDGLQl0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%2BD.%26aulast%3DXu%26aufirst%3DW.%2BH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%2BM.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B-cell-receptor%2520signalling%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span> <span> </span><span class="NLM_article-title">B-cell receptor signaling as a driver of lymphoma development and evolution</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2013.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.semcancer.2013.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=24060900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Srsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=410-421&author=C.+U.+Niemannauthor=A.+Wiestner&title=B-cell+receptor+signaling+as+a+driver+of+lymphoma+development+and+evolution&doi=10.1016%2Fj.semcancer.2013.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell receptor signaling as a driver of lymphoma development and evolution</span></div><div class="casAuthors">Niemann, Carsten U.; Wiestner, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6PA</span>),
    <span class="NLM_cas:pages">410-421</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The B-cell receptor (BCR) is essential for normal B-cell development and maturation.  In an increasing no. of B-cell malignancies, BCR signaling is implicated as a pivotal pathway in tumorigenesis.  Mechanisms of BCR activation are quite diverse and range from chronic antigenic drive by microbial or viral antigens to autostimulation of B-cells by self-antigens to activating mutations in intracellular components of the BCR pathway.  Hepatitis C virus infection can lead to the development of splenic marginal zone lymphoma, while Helicobacter pylori infection is assocd. with the development of mucosa-assocd. lymphoid tissue lymphomas.  In some of these cases, successful treatment of the infection removes the inciting antigen and results in resoln. of the lymphoma.  Chronic lymphocytic leukemia has been recognized for decades as a malignancy of auto-reactive B-cells and its clin. course is in part detd. by the differential response of the malignant cells to BCR activation.  In a no. of B-cell malignancies, activating mutations in signal transduction components of the BCR pathway have been identified; prominent examples are activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) that carry mutations in CD79B and CARD11 and display chronic active BCR signaling resulting in constitutive activation of the NF-κB pathway.  Despite considerable heterogeneity in biol. and clin. course, many mature B-cell malignancies are highly sensitive to kinase inhibitors that disrupt BCR signaling.  Thus, targeted therapy through inhibition of BCR signaling is emerging as a new treatment paradigm for many B-cell malignancies.  Here, we review the role of the BCR in the pathogenesis of B-cell malignancies and summarize clin. results of the emerging class of kinase inhibitors that target this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4y2VaqCqOLVg90H21EOLACvtfcHk0lj1J16X9ICG7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Srsb3F&md5=2ff0932e4c270986282ada8a9c6f453e</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2013.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2013.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DB-cell%2520receptor%2520signaling%2520as%2520a%2520driver%2520of%2520lymphoma%2520development%2520and%2520evolution%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D410%26epage%3D421%26doi%3D10.1016%2Fj.semcancer.2013.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Y.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lj1J16X9ICG7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Y.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0ljNYj-2SzFF1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib (PCI-32765), the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trials</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s11899-012-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1007%2Fs11899-012-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=23296407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1-6&author=J.+R.+Brown&title=Ibrutinib+%28PCI-32765%29%2C+the+first+BTK+%28Bruton%E2%80%99s+tyrosine+kinase%29+inhibitor+in+clinical+trials&doi=10.1007%2Fs11899-012-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials</span></div><div class="casAuthors">Brown Jennifer R</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib is a potent covalent kinase inhibitor that targets BTK.  BTK, or Bruton's tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia.  Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment.  As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and response associated with rapid increase in lymphocytosis, which then returns to baseline over time.  The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months.  In a cohort of untreated patients 65 years and over, the estimated 15 month PFS is 96 %.  Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmwv_ITNl9Dxgd2Wuil24tfW6udTcc2ebXsgF_IOgu-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D&md5=c64d7d8fa5d40a79ad029c9fb34248c3</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-012-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-012-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%2520%2528PCI-32765%2529%252C%2520the%2520first%2520BTK%2520%2528Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2529%2520inhibitor%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2013%26volume%3D8%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs11899-012-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="6a2e181f0d2a2c2e2b">[email protected]</a>, New Drug Application
2055520 Pharmacology Review(s).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Drug%40FDA%2C+New+Drug+Application%0A2055520+Pharmacology+Review%28s%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s40266-017-0468-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1007%2Fs40266-017-0468-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=28536906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=509-527&author=A.+Awauthor=J.+R.+Brown&title=Current+status+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+development+and+use+in+B-cell+malignancies&doi=10.1007%2Fs40266-017-0468-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies</span></div><div class="casAuthors">Aw, Andrew; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">509-527</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The B-cell receptor (BCR) pathway plays an important role in the survival, proliferation and trafficking of cancer cells in a variety of B-cell malignancies.  Recently, a no. of agents have been developed to target various components of the BCR pathway.  One such target is Bruton's tyrosine kinase (BTK), a Tec family kinase member found near the cell membrane that is involved in upstream BCR signaling.  The biol. function of BTK in several B-cell lymphoid malignancies has led to the development of the oral BTK inhibitor ibrutinib.  In chronic lymphocytic leukemia (CLL), ibrutinib has demonstrated durable clin. responses in relapsed/refractory (R/R) patients, including those with the high-risk del(17p) cytogenetic abnormality.  These findings have paved the way for trials evaluating ibrutinib in previously untreated CLL patients, and also in combination with chemoimmunotherapy or other novel agents.  Durable clin. responses have also been demonstrated in mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia (WM) patients treated with ibrutinib.  Ibrutinib is generally well tolerated, although current follow-up remains short and patients of advanced age are more likely to discontinue treatment for toxicity.  Treatment-specific side effects such as bleeding and atrial fibrillation may, at least partly, be related to off-target inhibition of non-BTK kinases.  Studies evaluating other potential indications for BTK inhibition are ongoing, including in post-allogeneic hematopoietic stem cell transplant patients for whom ibrutinib may be effective in modulating graft-vs.-host disease.  Combination trials of ibrutinib with venetoclax, a Bcl-2 inhibitor, are underway and are supported by sound preclin. rationale.  Several next-generation BTK inhibitors are under development with the goal of decreasing treatment-related toxicity and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6yK1USSJm3bVg90H21EOLACvtfcHk0lj6E-HAIhtPUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVSqtb4%253D&md5=24f1451099e7af18962a5778df3dea35</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40266-017-0468-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-017-0468-4%26sid%3Dliteratum%253Aachs%26aulast%3DAw%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DCurrent%2520status%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520development%2520and%2520use%2520in%2520B-cell%2520malignancies%26jtitle%3DDrugs%2520Aging%26date%3D2017%26volume%3D34%26spage%3D509%26epage%3D527%26doi%3D10.1007%2Fs40266-017-0468-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-86&author=J.+J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+L.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0lj6E-HAIhtPUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D86%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21-25&author=J.+J.+Wuauthor=M.+Z.+Zhangauthor=D.+L.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0ljFq8ma-AqZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DM.%2BZ.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26epage%3D25%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montraveta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Jensen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2841</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1158%2F1078-0432.CCR-16-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=27903679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2831-2841&author=S.+E.+M.+Hermanauthor=A.+Montravetaauthor=C.+U.+Niemannauthor=H.+Mora-Jensenauthor=M.+Gulrajaniauthor=F.+Krantzauthor=R.+Mantelauthor=L.+L.+Smithauthor=F.+McClanahanauthor=B.+K.+Harringtonauthor=D.+Colomerauthor=T.+Coveyauthor=J.+C.+Byrdauthor=R.+Izumiauthor=A.+Kapteinauthor=R.+Ulrichauthor=A.+J.+Johnsonauthor=B.+J.+Lannuttiauthor=A.+Wiestnerauthor=J.+A.+Woyach&title=The+Bruton+tyrosine+kinase+%28BTK%29+inhibitor+acalabrutinib+demonstrates+potent+on-target+effects+and+efficacy+in+two+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.CCR-16-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">Herman, Sarah E. M.; Montraveta, Arnau; Niemann, Carsten U.; Mora-Jensen, Helena; Gulrajani, Michael; Krantz, Fanny; Mantel, Rose; Smith, Lisa L.; McClanahan, Fabienne; Harrington, Bonnie K.; Colomer, Dolors; Covey, Todd; Byrd, John C.; Izumi, Raquel; Kaptein, Allard; Ulrich, Roger; Johnson, Amy J.; Lannutti, Brian J.; Wiestner, Adrian; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2841</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK.  We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL).  Exptl. Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model.  Mice received either vehicle or acalabrutinib formulated into the drinking water.  Results: Utilizing biochem. assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib.  In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLCγ2, ERK, and significant inhibition of CLL cell proliferation.  Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice.  Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLCγ2, and S6 was obsd.  Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle.  Conclusions: Treatment with acalabrutinib potently inhibits BTK in vivo, leading to on-target decreases in the activation of key signaling mols. (including BTK, PLCγ2, S6, and ERK).  In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment.  Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy in vivo on par with ibrutinib.  Clin Cancer Res; 23(11); 2831-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD7ESW1IqIY7Vg90H21EOLACvtfcHk0ljFq8ma-AqZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D&md5=a3c89f6918d1ed1195f4d439f33c17d7</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DMontraveta%26aufirst%3DA.%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DMcClanahan%26aufirst%3DF.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DWiestner%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520acalabrutinib%2520demonstrates%2520potent%2520on-target%2520effects%2520and%2520efficacy%2520in%2520two%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2831%26epage%3D2841%26doi%3D10.1158%2F1078-0432.CCR-16-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuhiro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 2452: ONO-4059, a novel oral Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2452</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-2452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1158%2F1538-7445.AM2013-2452" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2452&author=T.+Yasuhiroauthor=T.+Yoshizawaauthor=S.+Hottaauthor=Y.+Arizaauthor=Y.+Uedaauthor=R.+Kozakiauthor=J.+Birkett&title=Abstract+2452%3A+ONO-4059%2C+a+novel+oral+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor+that+demonstrates+potent+pharmacodynamic+activity+through+Phosphorylated+Btk+%28P-Btk%29+inhibition%2C+in+addition+to+effective+anti-tumour+activity+in+a+TMD-8+%28DLBCL%29+xenograft+model&doi=10.1158%2F1538-7445.AM2013-2452"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-2452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-2452%26sid%3Dliteratum%253Aachs%26aulast%3DYasuhiro%26aufirst%3DT.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DS.%26aulast%3DAriza%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DKozaki%26aufirst%3DR.%26aulast%3DBirkett%26aufirst%3DJ.%26atitle%3DAbstract%25202452%253A%2520ONO-4059%252C%2520a%2520novel%2520oral%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%2520that%2520demonstrates%2520potent%2520pharmacodynamic%2520activity%2520through%2520Phosphorylated%2520Btk%2520%2528P-Btk%2529%2520inhibition%252C%2520in%2520addition%2520to%2520effective%2520anti-tumour%2520activity%2520in%2520a%2520TMD-8%2520%2528DLBCL%2529%2520xenograft%2520model%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2452%26doi%3D10.1158%2F1538-7445.AM2013-2452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0lh4L8gBoAljTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BTK with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+D.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+BTK+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lh4L8gBoAljTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%2BD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520BTK%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+L.+Wangauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furmanauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lh6476H3X1tKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) Inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+C.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+Inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lgoJ7yosktgIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%2BC.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgoJ7yosktgIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+M.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Q.+Weiauthor=K.+Reifauthor=L.+C.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+a+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0ljhyt6d0K6W-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%2BM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%2BC.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0ljhyt6d0K6W-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of a small molecule inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-based+discovery+of+a+small+molecule+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lhykBt_oehNug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-based%2520discovery%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5112</span>– <span class="NLM_lpage">5128</span>, <span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+T.+Liauthor=Y.+Y.+Zuoauthor=G.+H.+Tangauthor=Y.+Wangauthor=Y.+Q.+Zhouauthor=X.+Y.+Wangauthor=T.+L.+Guoauthor=M.+Y.+Xiaauthor=N.+Dingauthor=Z.+Y.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0lhykBt_oehNug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BT.%26aulast%3DZuo%26aufirst%3DY.%2BY.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DT.%2BL.%26aulast%3DXia%26aufirst%3DM.%2BY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydro quinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+J.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+H.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.+R.+Wuauthor=C.+L.+Wangauthor=Y.+R.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+H.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+F.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydro+quinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%2BJ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BR.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydro%2520quinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Bruton’s tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2012.01415.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1111%2Fj.1747-0285.2012.01415.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=22594639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=366-373&author=H.+L.+Wanauthor=Z.+R.+Wangauthor=L.+L.+Liauthor=C.+Chengauthor=P.+Jiauthor=J.+J.+Liuauthor=H.+Zhangauthor=J.+Zouauthor=S.+Y.+Yang&title=Discovery+of+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+using+a+hybrid+protocol+of+virtual+screening+approaches+based+on+SVM+model%2C+pharmacophore+and+molecular+docking&doi=10.1111%2Fj.1747-0285.2012.01415.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking</span></div><div class="casAuthors">Wan, Hua-Lin; Wang, Ze-Rong; Li, Lin-Li; Cheng, Chuan; Ji, Pan; Liu, Jing-Jing; Zhang, Hui; Zou, Jun; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-373</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase has emerged as a potential target for the treatment for B-cell malignancies and autoimmune diseases.  Discovery of Bruton's tyrosine kinase inhibitors has thus attracted much attention recently.  In this investigation, we introduced a hybrid protocol of virtual screening methods including support vector machine model-based virtual screening, pharmacophore model-based virtual screening and docking-based virtual screening for retrieving new Bruton's tyrosine kinase inhibitors from com. available chem. databases.  Performances of the hybrid virtual screening approach were evaluated against a test set, which results showed that the hybrid virtual screening approach significantly shortened the overall screening time, and considerably increased the hit rate and enrichment factor compared with the individual method (SB-VS, PB-VS and DB-VS) or their combinations by twos.  This hybrid virtual screening approach was then applied to screen several chem. databases including Specs (202 408 compds.) and Enamine (980 000 compds.) databases.  Thirty-nine compds. were selected from the final hits and have been shifted to exptl. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWM-iX39A7ebVg90H21EOLACvtfcHk0ljp3E0xRh-8sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbfN&md5=eedf54c120aa2e10d2f87625d0bee570</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2012.01415.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2012.01415.x%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520using%2520a%2520hybrid%2520protocol%2520of%2520virtual%2520screening%2520approaches%2520based%2520on%2520SVM%2520model%252C%2520pharmacophore%2520and%2520molecular%2520docking%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2012%26volume%3D80%26spage%3D366%26epage%3D373%26doi%3D10.1111%2Fj.1747-0285.2012.01415.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Nonoshita, K.</span>; <span class="NLM_string-name">Shimamura, T.</span></span> <span> </span><span class="NLM_article-title">Novel Quinolone-substituted Compound</span>. <span class="NLM_patent">WO 2015/025936 A1</span>, February 26, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Uno&author=K.+Nonoshita&author=T.+Shimamura&title=Novel+Quinolone-substituted+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DT.%26atitle%3DNovel%2520Quinolone-substituted%2520Compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of pyrazolo[3,4-<i>d</i>]pyrimidines as tyrosine kinase RET inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2544</span>– <span class="NLM_lpage">2548</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.bmcl.2017.03.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2544-2548&author=C.+Y.+Wangauthor=H.+C.+Liuauthor=Z.+L.+Songauthor=Y.+C.+Jiauthor=L.+Xingauthor=X.+Pengauthor=X.+S.+Wangauthor=J.+Aiauthor=M.+Y.+Gengauthor=A.+Zhang&title=Synthesis+and+structure-activity+relationship+study+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+as+tyrosine+kinase+RET+inhibitors&doi=10.1016%2Fj.bmcl.2017.03.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.088%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BC.%26aulast%3DSong%26aufirst%3DZ.%2BL.%26aulast%3DJi%26aufirst%3DY.%2BC.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520tyrosine%2520kinase%2520RET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2544%26epage%3D2548%26doi%3D10.1016%2Fj.bmcl.2017.03.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0lhFi-BOpj-fQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Konteatis, Z.</span>; <span class="NLM_string-name">Moffett, K.</span>; <span class="NLM_string-name">Lee, Y.
H.</span>; <span class="NLM_string-name">Chao, W.
C.</span></span> Pyrrolotriazine Compounds. <span class="NLM_patent">WO 2010/126960 A1</span>, November 4, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Konteatis%2C+Z.%3B+Moffett%2C+K.%3B+Lee%2C+Y.%0AH.%3B+Chao%2C+W.%0AC.+Pyrrolotriazine+Compounds.+WO+2010%2F126960+A1%2C+November+4%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKonteatis%26aufirst%3DZ.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span>; <span class="NLM_string-name">Conlon, P.</span>; <span class="NLM_string-name">Erlanson, D. A.</span>; <span class="NLM_string-name">Fan, J. F.</span>; <span class="NLM_string-name">Guan, B.</span>; <span class="NLM_string-name">Hopkins, B. T.</span>; <span class="NLM_string-name">Ishchenko, A.</span>; <span class="NLM_string-name">Jenkins, T. J.</span>; <span class="NLM_string-name">Kumaravel, G.</span>; <span class="NLM_string-name">Marcotte, D.</span>; <span class="NLM_string-name">Powell, N.</span>; <span class="NLM_string-name">Scott, D.</span>; <span class="NLM_string-name">Taveras, A.</span>; <span class="NLM_string-name">Wang, D. P.</span>; <span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl Btk Inhibitors</span>. <span class="NLM_patent">WO 2011/029043 A1</span>, March 10, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Bui&author=P.+Conlon&author=D.+A.+Erlanson&author=J.+F.+Fan&author=B.+Guan&author=B.+T.+Hopkins&author=A.+Ishchenko&author=T.+J.+Jenkins&author=G.+Kumaravel&author=D.+Marcotte&author=N.+Powell&author=D.+Scott&author=A.+Taveras&author=D.+P.+Wang&author=M.+Zhong&title=Heteroaryl+Btk+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26atitle%3DHeteroaryl%2520Btk%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span>; <span class="NLM_string-name">Seenisamy, J.</span>; <span class="NLM_string-name">Liu-Bujalski, L.</span>; <span class="NLM_string-name">Potnick, J.</span>; <span class="NLM_string-name">Caldwell, R. D.</span>; <span class="NLM_string-name">Qiu, H.</span>; <span class="NLM_string-name">Neagu, C.</span>; <span class="NLM_string-name">Jones, R.</span>; <span class="NLM_string-name">Won, A. C.</span>; <span class="NLM_string-name">Goutopoulos, A.</span>; <span class="NLM_string-name">Sherer, B. A.</span>; <span class="NLM_string-name">Johnson, T. L.</span>; <span class="NLM_string-name">Gardberg, A.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl Compounds as Btk Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2016/057500 A1</span>, April 14, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Gaillard&author=J.+Seenisamy&author=L.+Liu-Bujalski&author=J.+Potnick&author=R.+D.+Caldwell&author=H.+Qiu&author=C.+Neagu&author=R.+Jones&author=A.+C.+Won&author=A.+Goutopoulos&author=B.+A.+Sherer&author=T.+L.+Johnson&author=A.+Gardberg&title=Heteroaryl+Compounds+as+Btk+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaillard%26aufirst%3DP.%26atitle%3DHeteroaryl%2520Compounds%2520as%2520Btk%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Lu, Z. J.</span>; <span class="NLM_string-name">Zhou, Y. B.</span>; <span class="NLM_string-name">Gao, A. H.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors</span>. <span class="NLM_patent">WO 2017/127371 A1</span>, July 27, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+B.+Liao&author=J.+Li&author=Z.+J.+Lu&author=Y.+B.+Zhou&author=A.+H.+Gao&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DX.%2BB.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of thieno[3,2-<i>c</i>]pyridin-4-amines as novel Bruton’s tyrosine kinase (BTK) inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6059</span>– <span class="NLM_lpage">6068</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1016%2Fj.bmc.2015.05.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=26277759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6059-6068&author=X.+G.+Zhaoauthor=M.+H.+Xinauthor=Y.+Z.+Wangauthor=W.+Huangauthor=Q.+Jinauthor=F.+Tangauthor=G.+Wuauthor=Y.+Zhaoauthor=H.+Xiang&title=Discovery+of+thieno%5B3%2C2-c%5Dpyridin-4-amines+as+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors&doi=10.1016%2Fj.bmc.2015.05.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors</span></div><div class="casAuthors">Zhao, Xinge; Xin, Minhang; Wang, Yazhou; Huang, Wei; Jin, Qiu; Tang, Feng; Wu, Gang; Zhao, Yong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6059-6068</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of BTK inhibitors bearing thieno[3,2-c]pyridin-4-amine framework as the core scaffold were designed, synthesized and well characterized.  In this paper, twenty one compds. displayed variant inhibitory activities against BTK in vitro, and compd. 14g showed the most potent inhibitory activity against BTK enzyme, with the IC50 value of 12.8 nM.  Moreover, compds. 14g displayed relatively good kinase selectivity and was subsequently evaluated in vivo for profiling its PK properties.  This work identified the thieno[3,2-c]pyridin-4-amine derivs. as novel BTK inhibitors and verified the value of thieno[3,2-c]pyridin-4-amine scaffold in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgi2j2x_zAQLVg90H21EOLACvtfcHk0liDd4MmjRPZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsb8%253D&md5=00266a30edeab1875d7321b6c230ae02</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.043%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%2BG.%26aulast%3DXin%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BZ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520thieno%255B3%252C2-c%255Dpyridin-4-amines%2520as%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6059%26epage%3D6068%26doi%3D10.1016%2Fj.bmc.2015.05.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiadeen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krikorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raaijmakers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu-Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-<i>a</i>]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+L.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.+B.+Alhassanauthor=Y.+N.+Yuauthor=H.+Vaccaroauthor=S.+L.+Liuauthor=C.+D.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=J.+de+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.+D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Mansuetoauthor=Z.+W.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20fR"><div class="casContent"><span class="casTitleNuber">20f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Liu, Jian; Guiadeen, Deodial; Krikorian, Arto; Gao, Xiaolei; Wang, James; Boga, Sobhana Babu; Alhassan, Abdul-Basit; Yu, Younong; Vaccaro, Henry; Liu, Shilan; Yang, Chundao; Wu, Hao; Cooper, Alan; de Man, Jos; Kaptein, Allard; Maloney, Kevin; Hornak, Viktor; Gao, Ying-Duo; Fischmann, Thierry O.; Raaijmakers, Hans; Vu-Pham, Diep; Presland, Jeremy; Mansueto, My; Xu, Zangwei; Leccese, Erica; Zhang-Hoover, Jie; Knemeyer, Ian; Garlisi, Charles G.; Bays, Nathan; Stivers, Peter; Brandish, Philip E.; Hicks, Alexandra; Kim, Ronald; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway.  It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases.  We report a series of compds. based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity.  Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket.  These interactions are evident in the X-ray crystal structure of the lead compds. 1 and 3 in the complex with the BTK enzyme.  Our lead compds. show desirable PK profiles and efficacy in the preclin. rat collagen induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNSbzZ9EmurVg90H21EOLACvtfcHk0liDd4MmjRPZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ&md5=62031c18108d12d36cb7f8e3c35888b7</span></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.%2BB.%26aulast%3DYu%26aufirst%3DY.%2BN.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DMansueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%2BW.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liDd4MmjRPZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1002/cpt.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fcpt.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=25669675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=455-468&author=Y.+Wangauthor=L.+L.+Zhangauthor=R.+E.+Champlinauthor=M.+L.+Wang&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+with+ibrutinib+in+B-cell+malignancies&doi=10.1002%2Fcpt.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies</span></div><div class="casAuthors">Wang, Y.; Zhang, L. L.; Champlin, R. E.; Wang, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-468</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The B-cell receptor signaling pathway, which is crit. to the development and maturation of normal B-cells, is emerging as an attractive therapeutic target in B-cell malignancies.  Ibrutinib is a potent irreversible inhibitor of Bruton's tyrosine kinase (Btk), a key kinase important for signal transduction in the B-cell receptor (BCR) pathway.  In preclin. studies, ibrutinib potently bound to Btk, inhibited BCR signaling, and decreased tumor cell proliferation and survival in many B-cell malignancy models.  Excellent safety and efficacy data in clin. trials have led to US Food and Drug Administration (FDA) approval of ibrutinib for previously treated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), as well as CLL with 17p deletion.  Ongoing clin. studies have also demonstrated great potency of ibrutinib in treating other types of non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Waldenstroem's macroglobulinemia (WM).  Combination of ibrutinib with chemoimmunotherapy and other promising novel agents in B-cell malignancy therapy has also been under clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4WL6Xb_Qdq7Vg90H21EOLACvtfcHk0ljUQ59kjKh1rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWisLk%253D&md5=f74d5fa50e5d8dd9689699f64646eb0b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcpt.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.85%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%2BL.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DWang%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520ibrutinib%2520in%2520B-cell%2520malignancies%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2015%26volume%3D97%26spage%3D455%26epage%3D468%26doi%3D10.1002%2Fcpt.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholzen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdes, J.</span></span> <span> </span><span class="NLM_article-title">The Ki-67 protein: from the known and the unknown</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10653597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=311-322&author=T.+Scholzenauthor=J.+Gerdes&title=The+Ki-67+protein%3A+from+the+known+and+the+unknown&doi=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Ki-67 protein: from the known and the unknown</span></div><div class="casAuthors">Scholzen, Thomas; Gerdes, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-322</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review with 95 refs.  The expression of the human Ki-67 protein is strictly assocd. with cell proliferation.  During interphase, the antigen can be exclusively detected within the nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes.  The fact that the Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells (Go), makes it an excellent marker for detg. the so-called growth fraction of a given cell population.  In the first part of this study, the term Proliferation marker is discussed and examples of the applications of anti-Ki-67 protein antibodies in diagnostics of human tumors are given.  The fraction of Ki-67-pos. tumor cells (the Ki-67 labeling index) is often correlated with the clin. course of the disease.  The best-studied examples in this context are carcinomas of the prostate and the breast.  For these types of tumors, the prognostic value for survival and tumor recurrence has repeatedly been proven in uni- and multivariate anal.  The prepn. of new monoclonal antibodies that react with the Ki-67 equiv protein from rodents now extends the use of the Ki-67 protein as a proliferation marker to lab. animals that are routinely used in basic research.  The second part of this review focuses on the biol. of the Ki-67 protein.  Our current knowledge of the Ki-67 gene and protein structure, mRNA splicing, expression, and cellular localization during the cell-division cycle is summarized and discussed.  Although the Ki-67 protein is well characterized on the mol. level and extensively used as a proliferation marker, the functional significance still remains unclear.  There are indications, however, that Ki-67 protein expression is an abs. requirement for progression through the cell-division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH90qONVnezrVg90H21EOLACvtfcHk0ljUQ59kjKh1rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Ggsg%253D%253D&md5=8ff8ab674303ccf7d324ca3c770eeb8a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4652%2528200003%2529182%253A3%253C311%253A%253AAID-JCP1%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DScholzen%26aufirst%3DT.%26aulast%3DGerdes%26aufirst%3DJ.%26atitle%3DThe%2520Ki-67%2520protein%253A%2520from%2520the%2520known%2520and%2520the%2520unknown%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2000%26volume%3D182%26spage%3D311%26epage%3D322%26doi%3D10.1002%2F%28SICI%291097-4652%28200003%29182%3A3%3C311%3A%3AAID-JCP1%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameriks, M. K.</span></span> <span> </span><span class="NLM_article-title">Development of a flexible strategy towards FR900482 and the mitomycins</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7890</span>– <span class="NLM_lpage">7903</span>, <span class="refDoi"> DOI: 10.1002/chem.201003489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=10.1002%2Fchem.201003489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=21618622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7890-7903&author=B.+M.+Trostauthor=B.+M.+O%E2%80%99Boyleauthor=W.+Torresauthor=M.+K.+Ameriks&title=Development+of+a+flexible+strategy+towards+FR900482+and+the+mitomycins&doi=10.1002%2Fchem.201003489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Flexible Strategy towards FR 900482 and the Mitomycins</span></div><div class="casAuthors">Trost, Barry M.; O'Boyle, Brendan M.; Torres, Wildeliz; Ameriks, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7890-7903, S7890/1-S7890/136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">FR 900482 (I) and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biol. mechanisms and obvious structural similarity.  Both classes possess potent anticancer activity, a feature that has led to their investigation and implementation for the clin. treatment of human cancer.  Given the structural similarity between these natural products, we envisioned a common synthetic strategy by which both classes could be targeted through assembling the mitomycin skeleton prior to further oxidative functionalization.  Realization of this strategy with respect to FR 900482 was accomplished through the synthesis of 7-epi-FR 900482, which displayed equal potency relative to the natural product against two human cancer cell lines.  With the challenging goal of a synthesis of either mitomycin or FR 900482 in mind, several methodologies were explored.  While not all of these methods ultimately proved useful for our synthetic goal, a no. of them led to intriguing findings that provide a more complete understanding of several methodologies.  In particular, amination via π-allyl palladium complexes for the synthesis of tetrahydroquinolines, eight-membered heterocycle formation via carbonylative lactamization, and amination through late-stage C-H insertion via rhodium catalysis all featured prominently in our synthetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ735AhxJdT7Vg90H21EOLACvtfcHk0li5cpX05myO4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslKmtLY%253D&md5=45504b5f1d935cd3a145f11f9aa434ca</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fchem.201003489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201003489%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DB.%2BM.%26aulast%3DTorres%26aufirst%3DW.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26atitle%3DDevelopment%2520of%2520a%2520flexible%2520strategy%2520towards%2520FR900482%2520and%2520the%2520mitomycins%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2011%26volume%3D17%26spage%3D7890%26epage%3D7903%26doi%3D10.1002%2Fchem.201003489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span>; <span class="NLM_string-name">Gao, Y. X.</span>; <span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Ni, H. H.</span>; <span class="NLM_string-name">Mulvihill, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Nicotinimide Inhibitors of Btk and Their Preparation and Use in the Treatment of Cancer, Inflammation and Autoimmune Disease</span>. <span class="NLM_patent">WO 2015/048662 A2</span>, April 2, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=X.+Y.+Chen&author=Y.+X.+Gao&author=C.+Liu&author=H.+H.+Ni&author=M.+Mulvihill&title=Substituted+Nicotinimide+Inhibitors+of+Btk+and+Their+Preparation+and+Use+in+the+Treatment+of+Cancer%2C+Inflammation+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BY.%26atitle%3DSubstituted%2520Nicotinimide%2520Inhibitors%2520of%2520Btk%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%252C%2520Inflammation%2520and%2520Autoimmune%2520Disease%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN','PDB','3GEN'); return false;">PDB: 3GEN</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00441">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_81651"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00441">10.1021/acs.jmedchem.8b00441</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>spectra of all new compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_002.csv">CSV</a>)</p></li><li><p class="inline">Crystallographic information files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_003.cif">CIF1</a>, <a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_004.cif">CIF2</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_001.pdf">jm8b00441_si_001.pdf (3.79 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_002.csv">jm8b00441_si_002.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_003.cif">jm8b00441_si_003.cif (27.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00441/suppl_file/jm8b00441_si_004.cif">jm8b00441_si_004.cif (13.33 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-10%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00441" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00441" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e108812dd9247f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
